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European Association of Cardiothoracic Anaesthesiologists (EACTA)Transfusion of allogeneic blood products during and after
cardiac operations is common. When the degree of ane-
mia and the consequent decrease in oxygen delivery
lead to organ ischemia, there is little doubt that red blood
cell (RBC) transfusion is necessary. In addition, treat-
ment with fresh-frozen plasma and platelets may be nec-
essary to support coagulation. Treatment with blood
products may also aim to prevent hemodynamic instabil-
ity from excessive postoperative blood loss. A large body
of evidence, however, indicates that transfusion of blood
products per se may be associated with increased morbid-
ity and mortality after cardiac operations.1-4 It is there-
fore important to assess the real versus perceived need
for the transfusion of allogeneic RBCs and other bloodFrom the Department of Cardiothoracic-vascular Anesthesia and Intensive Care,a
IRCCS Policlinico S. Donato, Milan, Italy; the Department of Anesthesiology,b
Duke University Medical Center, Durham, NC; the Working Group on Periopera-
tive Hemostasis,c Department of Anaesthesia, Ludwig Maximilian University
Muenchen, Munich, Germany; SouthEast Texas Cardiovascular Surgery Associ-
ates, PA,d Houston, Tex; Centre for Population Health Research,e Curtin Health In-
novation Research Institute (CHIRI), Curtin University, Perth, Western Australia;
the Medical Society for Blood Management,f Laxenburg, Austria; the Department
of Anesthesia,g Toronto General Hospital, University Health Network, University
of Toronto, Toronto, Ontario, Canada; the Department of Vascular Medicine and
Internal Medicine,h Academic Medical Center, University of Amsterdam, Amster-
dam, The Netherlands; the Bristol Heart Institute,i University of Bristol, Bristol
Royal Infirmary, Bristol, United Kingdom; the Division of Cardiothoracic Surgery,j
Alpert Medical School of Brown University, Rhode Island Hospital, Providence,
RI; the Department of Anesthesiology,k Cardiothoracic Anesthesiology, Monte-
fiore Medical Center, Bronx, NY; and the Department of Anaesthesiology and In-
tensive Care Medicine,l Charite-Universit€atsmedizin Berlin, Berlin, Germany.
Disclosures: The author group comprises the International Initiative on Haemostasis
Management in Cardiac Surgery (IIHMCS). Members of the group were compen-
sated for their presence at face-to-face meetings but not for the time invested in de-
veloping and reviewing the manuscript. Meeting organization and medical writing
support for literature searches and manuscript preparation were provided by Phy-
siciansWorld Europe GmbH, Mannheim, Germany. Costs incurred for travel, hotel
accommodation, meeting facilities, honoraria and preparation of the manuscript
were supported by an unrestricted educational grant from Novo Nordisk Health
Care AG, Zurich, Switzerland. The sponsor had no authorship or editorial control
over the content of the meetings or any subsequent publication.
Drs Marco Ranucci and Solomon Aronson are co–first authors and cochairs of the In-
ternational Initiative for Haemostasis Management in Cardiac Surgery (IIHMCS).
Received for publication Jan 24, 2011; revisions received Feb 9, 2011; accepted for
publication April 8, 2011; available ahead of print May 23, 2011.
Address for reprints: Marco Ranucci, MD, Department of Cardiothoracic-vascular
Anesthesia and Intensive Care, IRCCS Policlinico S. Donato, Via Morandi 30,
San Donato Milanese, Milan, 20097, Italy (E-mail: cardioanestesia@virgilio.it).
0022-5223/$36.00
Copyright  2011 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2011.04.007
The Journal of Thoracic and Cardproducts by examining the risk–benefit profile of blood
product transfusion relative to the clinical condition of
the patient. The risk–benefit profile of blood product trans-
fusion depends onmany factors but is primarily based on the
hemoglobin value. Other important factors include patient
age, sex, hemodynamic profile, and signs of organ dysfunc-
tion.5,6 The risks of infectious disease transmission1 and im-
munologic suppression,7 the costs, and a diminishing blood
supply also contribute to the direct risk–benefit decision
analysis and the overarching impetus to develop alternatives
to blood component transfusion. The decision-making proc-
esse that determines whether to transfuse, when to transfuse,
which blood products to transfuse, and how much of any
product to transfuse are indeed complex and need to include
an evaluation of both the risks of transfusion and periopera-
tive anemia and a discussion about blood conservation
strategies.
This topic was addressed by a comprehensive document
on perioperative blood conservation in cardiac surgery re-
leased by the Society of Thoracic Surgeons and the Soci-
ety of Cardiovascular Anesthesiologists.8 This document
provides guidelines for the use of RBCs, fresh-frozen
plasma, and platelets in the setting of a cardiac operation,
providing appropriate hemoglobin cutoff values for eryth-
rocyte transfusions, which vary widely depending on the
clinical scenario. Although these guidelines address
a number of very important issues and are largely fol-
lowed in the structured context of clinical studies, the rec-
ommendations have not been widely accepted in clinical
practice, as was recently demonstrated by a survey among
anesthesiologists.9 This lack of acceptance may be attrib-
utable to a perceived lack of evidence, a lack of awareness
of the guidelines, logistic issues related to the blood sup-
ply, institutional dogma, or policies that are based on eco-
nomic considerations. Any or all of these factors may
contribute to a reluctance to change institutional patient
blood management.
The concept of patient blood management includes dif-
ferent strategies that aim to avoid unnecessary transfusions.
The pillars that contribute to this concept are (1) the
optimization of patient RBC mass, (2) the minimization
of blood loss, and (3) the optimization of physiologic
anemia tolerance. The comprehensive concept of patient
blood management may soon replace the more simplisticiovascular Surgery c Volume 142, Number 2 249.e1
Abbreviations and Acronyms
ACS ¼ acute coronary syndrome
ACT ¼ activated clotting time
ANH ¼ acute normovolemic hemodilution
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
HES ¼ hydroxyethyl starch
ICER ¼ incremental cost-effectiveness ratio
ICU ¼ intensive care unit
IIHMCS ¼ International Initiative on
Haemostasis Management in
Cardiac Surgery
mini-CPB ¼ minimal cardiopulmonary bypass
RBC ¼ red blood cell
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rFVIIa ¼ recombinant activated factor VII
rSO2 ¼ regional cortical oxygen saturation
ScvO2 ¼ central venous oxygen saturation
SvO2 ¼ mixed venous oxygen saturation
TRICC ¼ Transfusion Requirements in Critical
Care
TTDR ¼ total transfusion dependency ratio
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approaches.
At present, patient management is highly heterogeneous
in different countries and institutions, and the recognition
that allogeneic blood products may do harm does not
seem to bewidespread. A recent survey of nearly 25,000 pa-
tients undergoing coronary artery bypass grafting (CABG)
in US institutions followed up from hospital admission until
30 days after discharge found large interinstitutional differ-
ences, accounting for 30% of the variance in transfusion
practices. Allogeneic blood use ranged from 50% to
100% among patients at different institutions, and 78.5%
of the male and 93.6% of the female patients received allo-
geneic blood products during the hospital stay, implying
that many of these transfusions may have been unneces-
sary.10 Similarly, a clinical trial comparing functional out-
come after administration of a liberal versus restrictive
transfusion regimen showed no benefit for the liberal
transfusion group.11
The authors of this article comprise the International Ini-
tiative on Haemostasis Management in Cardiac Surgery
(IIHMCS). We believe that many of the factors that influ-
ence the decisions and behavior surrounding transfusion
of allogeneic blood products are not adequately addressed
by the existing literature. One reason for this may be the
lack of information available within existing databases
used to determine the risk of transfusion during and after
cardiac operations. Whereas traditional guideline and con-249.e2 The Journal of Thoracic and Cardiovascular Ssensus papers review the weight of evidence to establish
a rationalization for a position or plan of action, we have
here sought to evaluate the evidence that exists to establish
a ‘‘call to action’’ to fill the gaps and define the needs for
further evidence.
The aims of this article are as follows: (1) to assess the
level of evidence for indications and risk factors associated
with transfusion of allogeneic RBCs and other blood
products, (2) to identify evidence gaps and prioritize the
evidence gaps with respect to potential impact on modify-
ing practice and outcomes, and (3) to recommend possible
actions to fill the evidence gaps, including but not limited
to defining perioperative factors that should in future be
included in existing databases.
MATERIALS AND METHODS
Comprehensive computer database literature searches were performed
with the indexed online database MEDLINE/PubMed. Lists of cited liter-
ature within relevant articles and our own libraries were also screened. The
primary intention of the review was to identify prospective randomized,
controlled trials (RCTs), existing systematic reviews, and current guide-
lines. Boolean operators andMedical Subject Heading thesaurus keywords
were applied as a standardized use of language to unify differences in
terminology into single concepts. The scientific questions posed and the
Medical Subject Heading headings applied to each search are listed in
Appendix Table 1. Searches were limited to English-language abstracts
and human studies, all in adults at least 19 years old, and the time period
was limited to between January 1994 and April 2009. Full publications
were retrieved on the basis of evaluated abstracts that were deemed relevant
to the queries posed.
This author group comprises an international, multidisciplinary med-
ical collaboration, the International Initiative on Haemostasis Manage-
ment in Cardiac Surgery (IIHMCS), with both interest and expertise in
the perioperative management of bleeding associated with cardiac sur-
gery blood conservation and transfusion avoidance. The IIHMCS group
includes members with specialties in cardiac surgery, cardiac anesthesia,
hematology, and medical economics. As IIHMCS authors, we performed
the selection of the scientific inquiries to be addressed, the screening and
review of the literature to be included, the formulation of a summary of
each section, and the complete manuscript review. The group participated
in 2 face-to-face meetings in February and October 2009 and a web
conference in July 2009 as part of the manuscript development process.
The IIHMCS group was managed by Physicians World Europe GmbH,
Mannheim, Germany, and its activities were supported by an unrestricted
educational grant from Novo Nordisk Health Care AG, Zurich,
Switzerland.
RESULTS AND DISCUSSION
Physiologic Signs of Organ Dysoxia
Adequate organ oxygenation is fundamental for physio-
logic organ function. Normally, the amount of oxygen de-
livered to the whole body exceeds resting oxygen
requirements by several fold.12 Tissue hypoxia occurs if
oxygen delivery, defined as the product of arterial oxygen
content and cardiac output, decreases to a level at which
it is no longer adequate to meet the metabolic demands of
the organs. Because hemoglobin-bound oxygen represents
a major fraction of arterial oxygen content, increasing he-
moglobin levels by RBC transfusion appears to be a logicalurgery c August 2011
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ment or prevention of imminent inadequate tissue oxygen-
ation is therefore a generally accepted indication for
RBC transfusion.13 Blood transfusion aims to improve the
oxygen transport capacity of the blood and therefore tissue
oxygenation. It is not, however, clear whether more oxygen
is actually delivered to the microcirculation after RBC
transfusion.14,15
The evidence base on which RBC transfusion is per-
formed is poor. Most RBC transfusions are administered
because the hemoglobin concentration or hematocrit has
fallen below a static, predefined threshold, which is per-
ceived to be associated with an insufficient arterial oxygen
content. This threshold varies widely between and even
within institutions. Across different countries and institu-
tions, 10% to 95% of patients undergoing cardiac surgery
reportedly received blood transfusions,16-19 suggesting that
many RBC transfusions, with their consequent transfusion-
associated morbidity, may have been unnecessary.
Low preoperative hemoglobin concentrations and reduced
intraoperative oxygen delivery have been shown to increase
postoperative morbidity.20-22 In a retrospective study, low he-
matocrit was associatedwith worse outcome; however, trans-
fusion, analyzed as a covariable, exacerbated this effect with
an additional increase in morbidity.23 Detrimental effects of
elevated hematocrit have also been demonstrated in a pro-
spective observational study: a hematocrit of at least 34%
on entry into the intensive care unit (ICU) was associated
with higher rates of acute myocardial infarction, left
ventricular dysfunction, and death after CABG.24 Both an
analysis of observational studies published between 1966
and June 200725 and a more recent large cohort study26
showed that RBC transfusion is associated with increased
perioperative and long-term morbidity and mortality, includ-
ing renal dysfunction, bacteremia, surgical site infection,
stroke, and prolonged ventilation.
From a clinical perspective, it is desirable to find more
reliable and measurable predictors for adequate organ
oxygenation. From the physiologic perspective, it is
therefore worthwhile to replace the static hemoglobin
transfusion trigger with a physiologic trigger that reflects
the true oxygen demands of the body and of sensitive
organs.27,28
Microcirculation. A review of the available literature
shows controversial and confounding results, and in several
studies RBC transfusion was not found to improve oxygen
supply to specific organs.29 Experimental data suggest that
the age of the transfused RBCs influences improvements in
oxygen carrying capacity and microcirculation after blood
transfusion30 and that transfusion of older RBCs with
impaired flexibility results in decreased oxygen upload in
the lungs, diminished oxygen carrying capacity, and ob-
struction of tissue capillaries, with the consequence of im-
paired transfusion outcomes.31,32 In a study of patientsThe Journal of Thoracic and Cardwith severe sepsis necessitating RBC transfusions, storage
time had no influence on the microvascular response to
RBC transfusion; however, an improvement in sublingual
microcirculation by RBC transfusion was only seen
in patients with altered capillary perfusion at baseline.33
In patients undergoing CABG, duration of RBC storage
was not associated with adverse outcome in some stud-
ies,34,35 whereas the transfusion of blood stored for longer
than 14 days was associated with a significantly increased
risk of postoperative complications in another study.36 Be-
cause data on the microcirculation were not reported in
these studies, it remains unclear whether decreased oxygen
uploading and diminished oxygen carrying capacity by
older RBCs results in poor outcomes after transfusion in pa-
tients undergoing CABG. Clinically applicable methods for
measurement of parameters of the microcirculation are not
yet available. Effective therapeutic interventions to improve
the microcirculation with drugs or fluids are being
evaluated.37
Mixed venous and central venous oxygen saturations:
Indicators of global body dysoxia. In clinical practice, he-
moglobin concentration is used as a substitute for whole
body oxygenation and thus as a trigger for blood transfusion.
Hemoglobin concentration is, however, only a surrogate
marker for oxygen-carrying capacity or oxygen supply.
Mixed venous oxygen saturation (SvO2), the oxygen satura-
tion of venous blood in the pulmonary artery, may be a better
physiologicmarker of oxygen demand because it reflects the
balance between systemic oxygen delivery and consump-
tion. As clinical marker of systemic oxygen use, measure-
ment of SvO2 continues to be a critical component of the
hemodynamic monitoring of critically ill patients.
Patients who have undergone CABG exhibit a reduction
in SvO2 during early postoperative mobilization, a reduction
that may reflect reduced cardiac index and oxygen delivery
at the same time that oxygen consumption is increased. The
clinical consequences and underlying mechanism or mech-
anisms of the reduced SvO2 are not yet fully understood.
38
Decreases in SvO2, however, have been associated with
a poor prognosis in patients with septic shock39 or heart fail-
ure,40 and therapeutic interventions that aim to raise SvO2
have been tried during the resuscitation of critically ill
patients.
Measurement of SvO2 requires placement of a pulmonary
artery catheter. Because a central venous catheter is often
inserted in critically ill patients for monitoring and fluid ad-
ministration, measurement of central venous oxygen satura-
tion (ScvO2) may be an attractive alternative to monitoring
of SvO2. Although the trend indicated by either measure-
ment has demonstrated a clinical correlation in studies
involving patients undergoing elective neurosurgical opera-
tions,41 the disagreement between single measurements of
SvO2 and ScvO2, such as was found in a study in cardiac sur-
gical patients,42 may not always be clinically acceptable.iovascular Surgery c Volume 142, Number 2 249.e3
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rior vena cava, and SvO2, reflects the differences in oxygen
saturation between the superior vena cava, the inferior vena
cava, and blood emanating from the coronary sinus. Mea-
sured values of ScvO2 depend heavily on the position of
the catheter from which the blood is drawn, and differences
in blood oxygen saturation measured at the proximal and
distal ports of the pulmonary artery catheter may be related
to measures of myocardial oxygen use. Further studies
measuring coronary sinus blood oxygen content and flow
are needed to test this hypothesis.43
The indications for measuring saturation by ScvO2 versus
SvO2 have been the subject of much controversy.
44 It has
been argued that the utility of the latter parameter is limited:
there are no correlations with regional tissue oxygenation,
SvO2 provides no direct information about the relationship
between oxygen delivery and uptake, the measurement is
only valid during steady state, and no correlation exists
between SvO2 and cardiac output. Studies comparing
hemoglobin level with either SvO2 or ScvO2 as a transfusion
trigger are not currently available.
The brain. Measurement of brain oxygenation has been the
subject of a numberof reviews.45Many tools have beendevel-
oped to estimate brain oxygenation.46 The use of near-
infrared reflectance spectroscopy for assessment of bifrontal
regional cortical oxygen saturation (rSO2) in patients undergo-
ing CABG has demonstrated correlations between low rSO2
values and cognitive dysfunction,47,48 prolonged hospital
stay,49 and perioperative cerebrovascular accidents.50 The ce-
rebral oximeter has been used in a range of patients. Cerebral
deoxygenation has been shown to correlate with a variety of
adverse systemic outcomes, such as renal failure, prolonged
ventilation,50,51 and physical workload.52,53
In one RCT, inmany cases interventions to increase pump
flow during cardiopulmonary bypass (CPB), increase mean
arterial pressure, or normalize PaCO2 during CPB were suf-
ficient to return rSO2 rapidly to within the baseline range;
in others, however, multiple interventions were required at
various intervals, with an overall success rate of only
80%.54 The decrease of rSO2 during acute normovolemic
hemodilution (ANH) paralleled the decline of hemoglobin
concentration; significant increases in tissue oxygenation
in response to blood transfusion were also detected. Conse-
quently, it has been speculated whether rSO2 might replace
hemoglobin as a transfusion trigger.55 Extended exposure
to levels of ANH to 5.1 g/dL impaired cognitive function
and delayed memory in healthy volunteers. This cognitive
defect was reversible by retransfusion of autologous blood
and by increasing the hemoglobin to 7.2 g/dL.56 A compara-
ble effect could be obtained by increasing the PaO2 by
breathing 100% oxygen.57 Animal studies did not confirm
improved cerebral oxygenation by transfusion of stored
blood.58 It is therefore conceivable that a decrease in rSO2
reflects insufficient oxygen uptake of brain tissue. It remains249.e4 The Journal of Thoracic and Cardiovascular Squestionable, however, whether blood transfusion can
indeed improve oxygenation.
The kidney. Severe anemia from any cause may produce
congestive heart failure59 or result from heart failure.60 Va-
sodilatation caused by the accompanying tissue hypoxia
lowers the blood pressure, thus activating the sympathetic
nervous system. This causes peripheral vasoconstriction
and tachycardia to maintain blood pressure. This in turn ac-
tivates the renin–angiotensin–aldosterone system. The high
angiotensin II levels further increase renal and peripheral
vasoconstriction and increase aldosterone production. The
resultant reduction in renal blood flow and glomerular filtra-
tion rate can cause renal ischemia and fluid retention. The
renal insufficiency thus produced may in turn also cause
anemia through reductions in erythropoietin production
and erythropoietin bone marrow activity.12
Acute renal failure remains an important complication
associated with cardiac and major surgery. The main cause
is believed to be renal hypoperfusion and ischemia.61,62 Re-
nal vascular resistance is increased in relation to systemic
vascular resistance during cardiac surgery, partly as a result
of anemia,63 and this increase leads to a smaller fraction of
cardiac output perfusing the kidneys. In addition, mean
blood pressure is decreased, perfusion pressure is nonpulsa-
tile, and renal blood flow autoregulation is not operative
during CPB.63 These factors conceivably influence the de-
velopment of renal hypoperfusion and ischemia.
Hemodilution during CPB may also contribute to postoper-
ative renal dysfunction.20
On the basis of these considerations, it has been hypoth-
esized that the perioperative use of a vasodilating agent,
such as the calcium-channel blocker felodipine, could
prevent the release of hypoxanthine during rewarming and
that this prevention would be related to improved renal per-
fusion and oxygen supply.64 Renal uptake of the biomarker
hypoxanthine or neutrophil gelatinase–associated lipocalin
may be an indicator of maintained renal perfusion.64 Other
therapeutic interventions are under discussion.65 ‘‘Online’’
real-time measurement of renal oxygenation, however, is
not yet possible.
Splanchnic oxygen transport. Gut mucosal oxygenation,
as assessed by noninvasive tonometry, has been shown to be
a predictor of patient outcome in a variety of clinical settings,
including heart surgery and intensive care.66 This is probably
related to the fact that the gut is one of the first organ systems
to undergo ischemic injury at times of hemodynamic stress.67
Moreover, the central role of impaired gut barrier function in
driving the systemic inflammatory response syndrome and
multiorgan failure would explain why gastrointestinal integ-
rity is a predictor of outcome. It has been shown that although
gastrointestinal complications are uncommonafterCPB, they
are associated with very high mortality.68
Regional tissue hypoxia may develop despite apparently
stable hemodynamics, as suggested by episodes of gastricurgery c August 2011
TABLE 1. Common antithrombotics seen by the cardiac surgical patient
Drug Class Physiologic half-life (h) Timing relative to surgery Reversibility
Unfractionated heparin Thrombin and FXa inhibitor 1–1.5 Can be administered up to skin
incision
Yes
Low–molecular weight heparin FXa and thrombin inhibitor 2.5–4 Stop 12–24 h before incision Partial
Bivalirudin Direct thrombin inhibitor 0.5 Stop 2 before surgery No, but rapidly
metabolized
Aspirin (INN acetylsalicylic
acid)
Cyclooxygenase inhibitor Life of platelet Mildly controversial, usually
not discontinued
No
Clopidogrel bisulfate (INN
clopidogrel)
Thienopyridine ADP receptor
antagonist
Life of platelet Guidelines: stop 5 days before
surgery; practice: variable
No
Ticlopidine hydrochloride Thienopyridine ADP receptor
antagonist
Life of platelet Same No
Prasugrel hydrochloride Thienopyridine ADP receptor
antagonist
Life of platelet Unclear, more data needed No
Abciximab GP IIb/IIIa receptor antagonist Life of platelet Stop 24 h before incision Platelet transfusion
may partially reverse
(controversial)
Eptifibatide GP IIb/IIIa receptor antagonist 4–6 Stop 6–12 h before surgery No
Tirofiban GP IIb/IIIa receptor antagonist 4–6 Stop 6–12 h before surgery No
Fxa, Activated factor Xa; ADP, adenosine diphosphate; GP, glycoprotein.
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diac surgery.69 The increasing metabolic demand during
the immediate postoperative period may increase the risk
of tissue hypoxia. It has been demonstrated that the increas-
ing metabolic demand is compensated for by a combination
of increased oxygen extraction and blood flow, both in the
whole body and in the splanchnic region, and that the re-
gional oxygen extraction capability is well preserved for
a long period.70 The gastric mucosal pH continues to de-
crease, reaching its nadir several hours postoperatively.71
This suggests that a regional mismatch between oxygen de-
livery and demand may persist or develop after the stabili-
zation of systemic hemodynamics in the postoperative
period.72 More recent data,73 however, have shown that in-
testinal perfusion is sufficiently preserved with moderate
hemodilutional anemia caused by CPB (hematocrit 25%–
33%). Furthermore, in a prospective, randomized trial,
more profound hemodilution (hematocrit 20% vs 25%)
during normothermic CPB did not induce an increase in
gastrointestinal permeability, which is a surrogate parame-
ter for maintained gastrointestinal perfusion and oxygen
delivery.74
Areas of uncertainty and topics for further study. Organ
dysoxia is a leading cause of organ dysfunction, but
hemoglobin content is a poor surrogate marker for impaired
organ oxygenation. For the heart, and with limitations the
brain, direct markers of deoxygenation are measurable on-
line. For total oxygen consumption and thus for body dys-
oxia, SvO2 is the best available indicator. Although it is
still under debate in cardiac surgery whether ScvO2, in clin-
ical practice may substitute for SvO2, both are global param-
eters that do not reflect regional oxygen supply. To whatThe Journal of Thoracic and Cardextent an increase in hemoglobin concentration as a result
of transfusion enhances tissue and organ oxygenation is un-
clear and still under investigation. To date, a combination of
physiologic transfusion triggers and hemoglobin concentra-
tion, as suggested by Spahn and others,28,75 may best guide
improvement of organ oxygenation, but further research is
needed.
Clinical Assessment and Decision Making
Management of the underlying disease process affects
cardiac surgical bleeding, especially for patients with acute
coronary syndrome (ACS) who have intracoronary throm-
bosis. Treatment of these patients involves intense and ag-
gressive antithrombotic treatment on presentation.76,77
Approximately 10% of patients with ACS will undergo sur-
gical revascularization, and management of these patients
can be challenging because they are exposed to a variety
of antithrombotic agents, including platelet inhibitors (cy-
clooxygenase inhibitors, thienopyridines, glycoprotein IIb/
IIIa inhibitors) and anticoagulants (Table 1). In addition, pa-
tients may receive thrombolytic agents before surgery. Ex-
posure to these antithrombotic agents increases the risks of
perioperative bleeding, transfusions, and surgical reexplora-
tion for persistent hemorrhage or cardiac tamponade. In clin-
ical decision making for this patient population, it is
extremely important to minimize risk and improve patient
safety. Important clinical decisions include the timing of sur-
gery for patients exposed to antithrombotic agents before
surgery, the use of pharmacologic adjuncts to support hemo-
stasis during surgery, the timing of transfusion, and the type
of blood products transfused.When bleeding does occur, the
etiology can be difficult to diagnose. Advanced laboratoryiovascular Surgery c Volume 142, Number 2 249.e5
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clarifying the cause of bleeding, although practice patterns
remain highly variable. Thrombelastometry as a point-of-
care test potentially allows earlier diagnosis of hemostatic
abnormalities and specific identification of the type of dis-
turbances present during cardiac surgical procedures.78
Other, more platelet-specific, point-of-care tests are also
available to identify the severity and cause of platelet dys-
function, although the effectiveness of these tests in reducing
transfusion remains unclear.
The timing of surgery. In patients with ACS, the optimal
timing of surgery can be a difficult clinical decision. The de-
cision as to when to discontinue antithrombotic agents will
depend on the pharmacodynamic half-life for each agent as
well as on the potential lack of reversibility.8 For anticoag-
ulant therapy, this decision is relatively straightforward and
can be based on extensive clinical experience. Low–molec-
ular weight heparins should be discontinued 12 to 24 hours
before surgery to avoid excessive bleeding,8 because the an-
ticoagulant effect of low–molecular weight heparins may be
intense and is only partially reversible. Patients receiving
unfractionated heparin preoperatively are easier to manage
because reversal of the antithrombin effect with protamine
is possible; many surgeons therefore do not discontinue
unfractionated heparin before CABG.
The optimal timing of surgery in patients exposed to anti-
platelet agents is more difficult, because the effects of many
platelet inhibitors are irreversible or long acting, and the po-
tency of their platelet inhibition may be variable. Although
preoperative aspirin (INN acetylsalicylic acid) affects peri-
operative bleeding and transfusion, its effect on the surgical
patient is usually small. For the vast majority of patients
with ACS requiring urgent CABG, continuing aspirin until
surgery thus seems to be the best option. Aspirin is therefore
rarely discontinued before coronary revascularization.8 Pa-
tients on an aspirin regimen who undergo surgery are usu-
ally treated with platelet transfusion only when bleeding
is problematic, although the optimal timing and magnitude
of transfusion is unclear. A delay of 7 to 10 days to allow for
platelet function to normalize is impractical and risky for all
but the most elective cardiac surgical cases, and for most
patients aspirin is continued throughout the perioperative
period because the benefits of aspirin outweigh its small
impact on the need for transfusion.
The management of patients treated with more potent
antiplatelet medications is controversial. Glycoprotein
IIb/IIIa inhibitors can be divided into relatively short-
acting agents, such as eptifibatide and tirofiban, and long-
acting ones, such as abciximab. The shorter-acting agents
should optimally be discontinued 2 half-lives before sur-
gery (approximately 4–6 hours) The longer-acting glyco-
protein IIb/IIIa inhibitor abciximab should be discontinued
24 hours before surgery to avoid excessive bleeding and
transfusion.79,80249.e6 The Journal of Thoracic and Cardiovascular SManagement of patients exposed to thienopyridines be-
fore surgery is also controversial. Analysis from a large
clinical trial of patients presenting with ACS without ST-
segment elevation suggests that patients undergoing
CABG more than 5 days after exposure to aspirin and the
thienopyridine clopidogrel bisulfate (INN clopidogrel)
had no increased risk of blood loss, whereas patients who
underwent surgery within 5 days of exposure had a (not
significantly) increased risk of major bleeding.81 In
a more recent retrospective cohort analysis, patients with
ACS undergoing CABG within 5 days of receiving clopi-
dogrel bisulfate had a significantly increased risk for major
bleeding.82 Accordingly, guidelines from the Society of
Thoracic Surgeons recommend a 5- to 7-day washout pe-
riod after exposure to thienopyridine before surgery to
reduce the risk of bleeding.8
Delayed surgery for a patient with ischemic heart disease
is associated with risks, however, and many surgeons and
cardiologists are uncomfortable with long delays between
catheterization and surgical revascularization and may
proceed with urgent CABG despite increased bleeding
risk. These patients also usually remain hospitalized until
the operation, with associated costs. In addition, the optimal
waiting period for washout of the thienopyridine is unclear,
because the individual patient response to clopidogrel bisul-
fate is variable. Although guidelines recommend a washout
period of at least 5 days, a recent investigation suggested
that a shorter interval of only 3 days may be equally safe,
avoiding the increase in bleeding and transfusion that
occurs when no washout interval is implemented.83
Prasugrel hydrochloride is a recently approved thienopyr-
idine for patients with ACS that has a rapid onset of action
and a potent, more consistent, and long-lasting antiplatelet
effect.84 The combination of prasugrel hydrochloride and
aspirin demonstrated superior efficacy to that of clopidogrel
bisulfate and aspirin; however, non-CABG–related major,
life-threatening, and fatal bleeding was also found to be sig-
nificantly higher.84 Patients with a history of stroke, elderly
patients, and small patients had higher rates of severe and
life-threatening bleeding when treated with prasugrel hy-
drochloride. Also, patients who underwent CABG had
a 4-fold higher incidence of major bleeding when exposed
to prasugrel hydrochloride relative to clopidogrel bisulfate.
The optimal management algorithm for patients undergoing
surgery exposed to prasugrel hydrochloride is unclear, be-
cause experience with the drug is limited; however, post-
poning surgery for 5 to 7 days (the life of the platelet)
seems prudent when possible. Whether different manage-
ment strategies and a longer washout interval are needed
for patients exposed to prasugrel hydrochloride as opposed
to clopidogrel bisulfate or ticlopidine hydrochloride re-
mains unclear and will require further investigation.
Not surprisingly, registry data have documented signifi-
cant practice variability among surgeons caring for patientsurgery c August 2011
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sis from a large ACS trial suggests that preoperative dual
platelet inhibition may actually reduce postoperative ische-
mic events such asmyocardial infarction, possibly by limiting
microembolization in the vascular tree.86 Although platelet
function tests are available andwould intuitively seemuseful,
many clinical questions remain regarding their actual utility
to guide clinical decision making, including which test to
use, what degree of platelet inhibition is safe for surgery,
and how tomanage patientswith clinically relevant inhibition
of platelet function. These open questions are areas of active
clinical research and product development.
Timing of transfusion of RBCs and other blood prod-
ucts. The optimal trigger to transfuse packed RBCs during
or after surgery is unclear. Although guidelines exist, many
surgeons individually tailor therapy and transfuse blood
according to a clinical analysis that takes into account
a patient’s age and relative health, specifically a history of
stroke, neurologic impairment, and heart or other major or-
gan failure. Many surgeons and other clinicians consider
transfusion when the hematocrit falls below a certain thresh-
old, such as 21% or 24%, although these values are rather
arbitrary, and healthy patients can certainly tolerate greater
degrees of anemia. A better understanding of the decision-
making process behind the patient-specific use of RBC
transfusion is an important area of future clinical research.
The timing of transfusion in patients at high risk for bleed-
ing is also not clear. Prophylactic transfusions of platelets
have been suggested for patients exposed to abciximab,87
usually after discontinuation of CPB. For patients exposed
to thienopyridines or aspirin, many surgeons use a ‘‘wait
and see’’ approach that depends on clinical events and the
magnitude of postoperative chest tube drainage. Regardless
of the antiplatelet medication used, the decision to transfuse
platelets is relatively arbitrary and is based on clinical as-
sessment, without laboratory confirmation of systemic
platelet dysfunction. Results from a small study suggest
that near-patient impedance aggregometry measurements
may allow the identification of patients with enhanced risk
of platelet concentrate transfusion.88 Whether specific
platelet-directed functional analysis in the bleeding patient
will limit empiric platelet transfusion is unclear, however,
and is discussed in another section of this article.
Areas of uncertainty and topics for further study. The
management of patients exposed to anticoagulants before sur-
gery remains an area of significant practicevariability and un-
answered questions. Future topics for study include the
identification of an optimal time to proceedwith surgery after
the suspension of antithrombotic medications and the use of
point-of-care laboratory testing to guide the timingof surgery.
Perioperative Fluid and Hemodilution Management
ANH (intraoperative autologous donation). ANH is
a technique that removes whole blood while maintainingThe Journal of Thoracic and Cardeuvolemia immediately before operation. It is inexpensive
and efficient, it may preserve coagulation factors, and it
nearly eliminates clerical error. In theory, the method pre-
serves withdrawn blood from CPB degradation, decreases
the amount of autologous components lost to bleeding,
and provides fresh autologous whole blood for reinfusion
after CPB. ANH does not reduce bleeding but does appear
to reduce the need for allogeneic blood transfusions.89-97
The efficacy of ANH is limited by several factors, around
which a number of questions remain for future investiga-
tion, including the target for acute hemodilution, transfu-
sion triggers, and fluid type required to establish optimal
ANH. In a recent prospective RCT of hemodilution during
cardiac surgery with hypothermic (30C–32C) CPB in
adults, in which a target hematocrit of 27% was compared
with a target hematocrit of 17%, it was noted that neurocog-
nitive impairment was increased after extreme hemodilu-
tion.98 Although it has been suggested that blood loss
should exceed 70% of patient blood volume for ANH to
prevent homologous transfusion of at least 1 RBC unit,99
an optimal starting hemoglobin level has not been estab-
lished, nor has an optimal transfusion trigger. Clinical stud-
ies have suggested that patients with cardiovascular disease
can tolerate hemoglobin levels of 7.0 g/dL11,100 and that he-
modilution does not alter the coronary vasodilating effects
of endogenous or exogenous nitric oxide.101 The effect of
acute reduction in circulating hemoglobin levels by ANH
combined with significant surgical blood loss remains in
question, however, and the safe limits of hemodilution
have not been established.
To provide better understanding of the risks and benefits
of ANH, future investigation should focus on identifying
safe hemodilution limits according to patient subtype, along
with specific situational and conditional circumstances. For
example, a 40-year-old man without comorbidity may have
a different hemodilution target tolerance or transfusion
trigger threshold than a 70-year-old man with multiple
comorbidities.
Preoperative autologous RBC blood donation. Although
the safety of blood supplies is high in developed countries,
there is still concern about contraction of infections from
transfusion of allogeneic blood. Preoperative autologous
blood donation is the process by which patients donate
blood before elective surgery and subsequently receive their
own blood in the perioperative period if transfusion is
required. Theoretic advantages include the patient’s sense
of control over care, decreased risk of direct transmission
of viral infections, and avoidance of alloimmunization
from donor blood. Disadvantages include the inconve-
nience of donation weeks before the procedure, consider-
able operating costs, an inherent delay that may lead to
decreased effectiveness of stored blood oxygen delivery,
and an increased need for adequate replacement of lost
RBC mass before surgery. There also remains a risk ofiovascular Surgery c Volume 142, Number 2 249.e7
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cially for older people.
In a meta-analysis of 15 studies conducted in the 1980 and
1990, preoperative autologous blood donation decreased ex-
posure to allogeneic blood but increased exposure to any
transfusion (allogeneic, autologous, or both).102 This result
may have arisen because preoperative autologous blood
donation caused some preoperative anemia or because of
a more liberal transfusion policy when autologous blood
was available. In a recently published Cochrane meta-
analysis, the relative risk reduction for receiving an allogeneic
blood transfusion was 68% in patients with preoperative au-
tologousblooddonation relative to control groups,withanab-
solute risk reduction of 44%. The risk of receiving any blood
transfusion (allogeneic, autologous, or both) was actually in-
creased by preoperative autologous blood donation (relative
risk 1.24, 95% confidence interval 1.02–1.51).103
Only a single trial has assessed preoperative autologous
blood donation in cardiac surgery.104 In this small, prospec-
tive study, exposure to allogeneic blood products was
39.1% in the control group not undergoing preoperative au-
tologous blood donation, whereas 47.8% of patients in the
preoperative autologous blood donation group received any
blood product (P ¼ .73), including 16% exposed to alloge-
neic blood products (P ¼ .036 vs control).
The optimal method, amount, timing before surgery, and
most cost-effective approach to autologous blood donation re-
main undefined. Although the trials of preoperative
autologous blood donation have shown a reduction in the
need for allogeneic blood, the methodologic quality of
these trials was poor, and for most trials covered in the
Cochrane meta-analysis,103 allocation concealment was not
described. Because the overall transfusion rates were in-
creased by recruitment into the preoperative autologous blood
donation arms of the trials, these data raise questions about the
benefit of preoperative autologous blood donation. In the ab-
sence of large, high-quality trials with relevant clinical end
points, it is not possible to determine whether the benefits of
preoperative autologous blood donation outweigh the harms.
Because bias for the success or failure of this technique has
become more and more institutionally specific in recent
years,105 targeted studies that explore transferable assump-
tions from any given institution to another may be needed.
Acute preoperative platelet pheresis. Acute preoperative
platelet pheresis comprises withdrawal of autologous
platelet rich plasma immediately before surgery and reinfu-
sion after CPB. Several prospective randomized studies
have shown conflicting results for the efficacy of acute pre-
operative platelet pheresis in limiting bleeding and blood
transfusions after cardiac surgery,106-118 and a meta-
analysis concluded that acute preoperative platelet pheresis
was only marginally effective in trials of good quality.119
Despite some laboratory evidence of preserved coagula-
tion and fibrinolytic parameters, the clinical evidence does249.e8 The Journal of Thoracic and Cardiovascular Snot generally support this technique to reduce bleeding or
transfusion. It has been suggested that lack of standardiza-
tion may play a role, because some techniques result in
high-yield platelet salvage whereas others do not.119,120
The effectiveness of techniques that provide high-yield
platelet salvage to reduce bleeding or transfusion remains
to be demonstrated.
Hemostatic defects during cardiac surgery are influenced
by several mechanisms, including inhibition of platelet
aggregation and fibrinolysis. Heparin cannot completely
prevent generation of thrombin or fibrin,109 and it is not
clearly understood why acute preoperative platelet pheresis
appears to contribute to the stabilization of impaired platelet
function according to laboratory but not to clinical intravas-
cular hemostasis. Furthermore, it may be questionable
whether acute preoperative platelet pheresis is still effective
to reduce blood loss and transfusion requirements in times
of dual antiplatelet inhibition.
It appears that our assumptions and rationalizations re-
garding platelet and coagulation medicine are incomplete
and inadequate at this time. More basic research is needed
for a better understanding of why this technique does or
does not translate into the fulfillment of clinical reality.
Alternative volume replacement solutions, including
postoperative fluid management. Alternative intravascu-
lar fluid volume expansion options comprise fluids other
than crystalloid solutions. Overall, the data show that col-
loids maintain intravascular volume and regional tissue
perfusion better than do crystalloids, but there are differ-
ences among colloids when used for fluid management in
acutely ill patients with respect to the incidence of adverse
events. All hydroxyethyl starch (HES) solutions modify
coagulation function by interfering with fibrinogen, factor
VIII, von Willebrand factor, platelet function, fibrin
formation, and clot firmness. The degree of hemostatic im-
pairment caused by HES depends on the molecular weight,
degree of substitution, and rate and volume of infusion. A
new generation of more easily degraded HES solutions of
medium or lower molecular weight has therefore been de-
veloped to result in fewer effects on hemostasis while pro-
viding a similar volume-expanding effect.121-126 Gelatins
have unlimited dose recommendations but are associated
with allergic reactions127-129 and exhibit comparable effects
on the coagulation system.127-130 Human albumin has a neg-
ligible effect on coagulation but is expensive, in short sup-
ply, and itself a blood product.131
A number of studies have assessed the effect of the choice
of resuscitation fluid for patients in ICUs. In a multicenter,
double-blind RCT in a heterogeneous population of ICU pa-
tients, the use of either 4% albumin or normal 0.9% saline
solution for fluid resuscitation resulted in similar outcomes
at 28 days; however, effects on bleeding and transfusion
were not reported.132 A meta-analysis of 21 studies in adult
and pediatric patients undergoing cardiac and noncardiacurgery c August 2011
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a priming solution was associated with a lower drop in
platelet count and with a less positive fluid balance during
CPB, which resulted in a lower postoperative weight
gain.133 There was no benefit reported when albumin was
added to synthetic colloids in adult cardiac surgical
patients.134
In view of the lower costs of synthetic colloids, their use
has been considered a valuable alternative to albumin. In
a pooled analysis of 7 studies in major surgery that included
4 cardiac surgical trials, blood loss and transfusion require-
ments were lower for patients receiving HES 130/0.4 than
for those receiving HES 200/0.5.135
It remains uncertain when or whether the choice of resus-
citation fluid may affect perioperative bleeding or transfu-
sion requirements. RCTs that are carefully designed to
distinguish patient subtype, situation, and condition are
needed. For example, a 40-year-old man without comorbid-
ity during a low- or moderate-risk procedure may have
a different response (hemodilution target tolerance or
transfusion trigger threshold) than a 70-year-old man with
multiple comorbidities undergoing a high-risk procedure.
Areas of uncertainty and topics for further study. Future
investigation should focus on developing RCTs that identify
patient subtypes and both situational and conditional cir-
cumstances that influence the risk–benefit ratio associated
with ANH. Database analyses would facilitate more tar-
geted hypothesis generation to improve patient selection
criteria. In addition, exploration of newly developed data-
base sources, including health economic parameters, would
allow observational research to advance knowledge in this
area. Methodologic standardization of acute platelet plas-
mapheresis to establish procedural norms is also needed.
The available studies provide inadequate data from which
to draw firm conclusions regarding the effect of acute plate-
let plasmapheresis on clinically important end points, and
further study is required.
Cardiopulmonary Bypass
Pump type: Centrifugal versus roller. Centrifugal pumps
are nonocclusive pumps that produce a constrained vortex
by rotation of impellers or concentric bells. Roller pumps
are occlusive pumps that sequentially compress a segment
of the CPB circuit.
Platelet count and function are better preserved by
centrifugal pumps.136,137 It is therefore possible that
these pumps could limit postoperative bleeding and transfu-
sions. There are no RCTs demonstrating that centrifugal
pumps reduce transfusion rate or the amount of blood prod-
ucts used, perhaps because it is difficult to separate ‘‘pump
effect’’ from other confounders, because centrifugal pumps
are always used in the context of other techniques such as
minimal CPB (mini-CPB). Centrifugal pumps therefore
appear to be safer than roller pumps, but if used separatelyThe Journal of Thoracic and Cardfrom other techniques, pump type appears not to limit
transfusions.
Shed blood management: Closed versus open circuits.
Closed circuits are circuits with a collapsible venous reser-
voir and cardiotomy reservoir separated from the venous
line or circuits without a cardiotomy reservoir. Blood pro-
cessing includes washing and concentrating RBCs with
a cell saver. The air–blood interaction is a determinant of
platelet activation and hemolysis. Shed blood (blood col-
lected in the pericardial cavity) is conveyed into a cardiot-
omy reservoir and readministered to the patient when an
open circuit is used. This blood contains many products
that can activate the inflammatory, hemostatic, and fibrino-
lytic systems and can promote platelet activation.138-142 It
has therefore been hypothesized that the use of closed cir-
cuits with shed blood washing may limit postoperative
bleeding and the related transfusion needs.
There have been few studies to address the impact of
closed circuits on transfusion rates. Two studies143,144
found no significant differences in transfusion rate. One
RCT addressing the effects of cardiotomy blood processing
during and after CPB described no differences in transfu-
sion rate but did note a higher number of units transfused
in the group in which the cardiotomy blood was pro-
cessed.144 In contrast, an earlier study145 demonstrated
that shed blood processing resulted in less postoperative
bleeding, with a trend toward fewer allogeneic blood
transfusions.
Too few RCTs have investigated shed blood management
with respect to transfusion rates. Moreover, most of the pub-
lished studies include confounders implemented together
with closed circuits, such as biocompatible coatings, reduc-
tions in systemic heparinization, and centrifugal pumps.
The possibility remains that blood processing may be detri-
mental because of the loss of coagulation proteins.
Surface treatment of circuit and oxygenator. Surface
treatment of circuit and oxygenator includes any chemical
treatment that aims to increase the biocompatibility
of CPB materials. Much evidence exists that surface
treatments of CPB materials decrease the inflammatory
response to CPB,146-151 limit hemostatic activation,147,152
and preserve platelet function,148,153,154 even if thrombin
generation does not appear to be directly affected by these
treatments.155 It is therefore reasonable to hypothesize that
surface treatments would decrease allogeneic blood product
transfusion rate through a combination of these effects.
Approximately 40 RCTs have addressed the clinical im-
pact of CPB surface treatments on outcome after cardiac
surgical operations. The two largest RCTs156,157 failed to
identify significant differences in transfusion rates. Two re-
cent meta-analyses pooled the data from the available
RCTs.158,159 The first,158 which was limited to heparin-
bonding treatments and included 19 RCTs (2709 patients)
in the transfusion rate pooled analysis, concluded that theiovascular Surgery c Volume 142, Number 2 249.e9
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icant reduction in blood transfusion rate. The second anal-
ysis,159 which pooled all the different surface treatments
and analyzed 20 RCTs (3453 patients), again found a signif-
icant reduction in blood transfusion rate. When only the
high-quality studies were considered, however, the differ-
ence was no longer significant.
Although much information can be gathered from the
current literature with respect to CPB surface treatment
and transfusion rates, most studies to date have not in-
cluded a well-defined transfusion protocol and are hetero-
geneous with respect to the other material-independent
sources of blood activation, such as circuit type and
heparin management.
Reduced systemic heparinization. Anticoagulation to es-
tablish and maintain CPB may be achieved with a heparin
loading dose less than 300 IU/kg, with a target activated
clotting time (ACT) of at least 300 seconds, in association
with the use of biocompatible circuits and oxygenators.
Current heparinization practice (300–400 IU/kg with a tar-
get ACT of at least 400 seconds) is based more on tradition
than on evidence. One RCT160 demonstrated that a loading
dose of 200 IU/kg of heparin is sufficient to reach a target
ACTof 480 seconds, and that patients receiving less heparin
had a lower postoperative blood loss. Reduction of systemic
heparinization with heparin-coated circuits decreases
platelet activation.161 It is reasonable to hypothesize that
by decreasing the heparin dose and, as a consequence, the
protamine dose, both bleeding and transfusions may be
reduced.
A number of studies have demonstrated that reduced sys-
temic heparinization in association with biocompatible cir-
cuits is feasible and safe.161-168 A limited number of RCTs
have explored the impact of this technique on transfusion
rates. One RCT found no significant differences,162 whereas
others165,167 found a significant reduction in transfusion
rate.
The current evidence is based on the association between
biocompatible circuits (mainly heparin-bonded circuits)
and reduced systemic heparinization. No evidence exists
that the heparin dose and the target ACT can be safely re-
duced with conventional circuits. More RCTs are required
to clarify the impact of this technique on transfusion needs,
but a trend towards a beneficial effect exists. We suggest
that future studies focus more on the concept of ‘‘adequate
heparinization’’ rather than ‘‘reduced heparinization,’’ with
heparin concentration monitoring systems included in the
study design. Relevant fields to be included in the databases
are as follows: (1) heparin loading dose, (2) subsequent hep-
arin doses, (3) target ACT, and, whenever available, (4) hep-
arin sensitivity (s/[IU $ kg]). It may also be worthwhile to
measure thrombin generation, for example by thrombin–
antithrombin complexes or prothrombin fragment 1.2.249.e10 The Journal of Thoracic and Cardiovascular SHemodilution during CPB: Reduction techniques. He-
modilution during CPB is the lowest hematocrit or hemo-
globin value reached during CPB. Regardless of the
transfusion protocol applied, transfusions are always trig-
gered by levels of hemoglobin considered inadequate for
the patient’s needs. Because of the CPB priming solution,
additional fluids, and cardioplegia, various degrees of he-
modilution may be tolerated during CPB. It is reasonable
to hypothesize that low hematocrit values during CPB
may trigger transfusions during CPB and may result in
a low hematocrit in the early postoperative phases, trigger-
ing postoperative blood transfusions. Measures that aim to
limit hemodilution during CPB thus could limit both intra-
operative and postoperative transfusions.
Large database investigations have found an association
between the lowest hematocrit during CPB and postopera-
tive morbidity and mortality.20,169-174 Correction of hemo-
dilution with allogeneic blood transfusions, however, may
exacerbate the problem.20,171 Reduction of the CPB prim-
ing volume may help to limit hemodilution during CPB.
This can be achieved by minimizing tubing size and length
and using vacuum-assisted venous drainage or retrograde
autologous priming. A 2007 RCT175 demonstrated that re-
ducing priming volume from 1400 to 800 mL resulted in
a significantly lower rate of allogeneic blood transfusions.
Another study in 2006176 had found similar results.
Measures to reduce hemodilution during CPB are reason-
able and are often achieved by using mini-CPB in conjunc-
tion with other techniques. A priming volume reduction
may be achieved, however, even with conventional CPB
circuits.
Minimal CPB. Mini-CPB comprises the following simul-
taneous conditions: closed circuit (with or without collaps-
ible venous reservoir), centrifugal pump, reduced (<1000
mL) priming volume, biocompatible surface treatment,
and shed blood separation. Reduced systemic hepariniza-
tion may also be applied. Mini-CPB includes several strat-
egies that have a recognized or hypothesized effect on
allogeneic blood transfusions, so it is reasonable to hypoth-
esize that mini-CPB might show some synergistic effects.
At present, 8 RCTs175-182 have investigated transfusion
rates in patients undergoing mini-CPB relative to a control
group. Five of these studies175-179 found a significant bene-
ficial effect, whereas 3 of them180-182 found no differences,
mainly because of a limited patient population. A recent
meta-analysis of RCTs183 demonstrated that mini-CPB is
associated with a 60% reduction in blood transfusions
(odds ratio 0.4, 95% confidence interval 0.26-0.63). Mini-
CPB is a technique associated with a high level of evidence
for the limitation of blood transfusions.
Areas of uncertainty and topics for further study. There
are still areas of uncertainty about the role of CPB technique
and equipment in determining the transfusion needs. Theurgery c August 2011
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elucidated, and this is reflected in the widespread clinical
use of both systems. Larger studies on mini-CPB (which in-
corporates closed circuits) are needed. The main debate,
however, still revolves around the optimal dose and moni-
toring of heparinization and heparin reversal.
Adverse Outcome After Transfusion
The treatment aim of RBC transfusion is to reverse or
prevent incipient tissue hypoxia arising as a consequence
of acute hemorrhage or severe anemia. The efficacy of
transfusion in achieving this goal, however, has never
been evaluated in a high quality randomized study in car-
diac surgery. What evidence we have is largely derived
from observational clinical studies. Rather than show that
transfusion is efficacious, these studies appear to show an
apparently paradoxic association between RBC transfusion
and adverse outcome. Data from studies evaluating
associations between transfusion and perioperative mortal-
ity, sepsis, and ischemic syndromes, including cardiac and
renal complications,1,2,10,21,23,26,65,184-199 are summarized
in Figures 1 through 4.
Typically, these types of analyses use statistical approaches
to adjust for such confounding variables as differences in risk
profiles between transfused and nontransfused patients. The
analyses cannot, however, adjust for unmeasured con-
founders or for the likelihood that there will have been bias
in the prescription of allogeneic RBCs, with patients who
are more ill being more likely to receive transfusions than
those who are less ill. There is also a tendency toward report-
ing bias in these types of analyses. As such, we cannot claim
that the data displayed in Figures 1 through 4 demonstrate
causality. The significant heterogeneity in the definitions of
intervention (transfusion yes or no, massive transfusion yes
or no, number of units as a continuous variable) as well as
in definitions of outcomes in these studies precludes quantita-
tive meta-analyses. A qualitative review of the data, however,
demonstrates consistent and large effect sizes for associations
between transfusion and adverse outcomes across studies and
in different populations, and these are unlikely to be attribut-
able simply to confounding and bias. This data, it could be ar-
gued, are sufficient topresent anethical barrier tohigh-quality
randomized trials that might attempt to demonstrate a causal
relationship between transfusion and adverse outcome.When
one considers that as many as 100% of patients receive allo-
geneic blood components in some centers, it could also be ar-
gued that this level of evidence is not considered enough to
justify restrictive transfusion practice by many clinicians.
This represents objective evidence of clinical equipoise.
Moreover, if transfusion does cause adverse events, there is
a clinical responsibility to demonstrate this. This is a rationale
for a multicenter randomized trial designed to demonstrate
a causal relationship between transfusion and adverse
outcome.The Journal of Thoracic and CardioSuch a trial would presumably be designed along the
lines of the pivotal Transfusion Requirements in Critical
Care (TRICC) study published more than a decade
ago.200 This remains the only high-quality RCT that has
sought to detect differences in clinical efficacy between 2
transfusion indications in adults, and it offers some evi-
dence that transfusion causes organ injury. This study, per-
formed in critical care patients, compared a restrictive
transfusion threshold (7.0 g/dL) with a liberal transfusion
threshold (10.0 g/dL). A total of 100% of those in the liberal
group received an allogeneic RBC transfusion, compared
with 67% in the restrictive group. Although there was no
difference in the primary end point (30-day mortality) be-
tween the groups, there were some differences in secondary
end points, including myocardial infarction and pulmonary
edema. Allogeneic RBC storage methods have progressed
in the last decade, with universal leukodepletion being
used in many countries, and there is limited homology
between the highly selected group of patients randomly
allocated in TRICC and those undergoing cardiac surgery.
For example, the TRICC patients were on average at least
10 years younger than those reported in most series in
adult cardiac surgery, and only 20% of the patients in
the TRICC study had cardiovascular disease. Although
a subgroup analysis from the TRICC study confirmed
that a restrictive RBC transfusion strategy generally ap-
pears to be safe in most critically ill patients with cardio-
vascular disease, patients with severe ischemic heart
disease were the only subgroup in which the restrictive
group had lower (though nonsignificantly) absolute sur-
vival than the patients in the liberal group.11 We therefore
need a similar study in cardiac surgical patients. Multicen-
ter RCTs are expensive and difficult to perform, and they
must be carefully designed.201 The relative costs of such
studies can be justified, however, by the potential eco-
nomic cost of transfusion-associated morbidity. In 1 anal-
ysis, transfusion increased the average cost of a cardiac
procedure by as much as 40%.26
There is some evidence that the relationship between
transfusion and adverse outcome is affected by donor blood
processing and storage duration. Prestorage leukodepletion
has been reported to reduce transfusion-associated morbid-
ity in meta-analyses of RCTs in cardiac surgery202; how-
ever, significant heterogeneity in the types of products
compared in these trials, as well as in the methods of
analysis, have recently called these conclusions into
question.203,204 In many countries, this issue is no longer
relevant because of the introduction of universal leukode-
pletion as a theoretically motivated strategy for the reduc-
tion of prion transmission.
Prolonged RBC storage duration has been shown to in-
crease the frequency of adverse events attributable to trans-
fusion in some reports36 but not in others,35,205 although
there is a strong experimental basis in favor of believingvascular Surgery c Volume 142, Number 2 249.e11
FIGURE1. Forest plot of studies evaluating the effect of red blood cell transfusion on perioperativemortality (in-hospital or 30-daymortality). IV, Inclusive
value; CI, confidence interval.
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is characterized by loss of nitric oxide bioavailability, de-
formability, and high-energy phosphate depletion in erythro-
cytes, as well as by accumulation of phospholipids and other
toxic species in the supernatant.206 Experimental transfusion
of stored cells produces more organ injury and tissue hyp-
oxia than does transfusion of fresh RBCs, although the ho-
mology between current experimental models and human
RBC transfusion is limited. Reduction of RBC storageFIGURE 2. Forest plot of studies evaluating the effect of red blood cell tran
IV, Inclusive value; CI, confidence interval.
249.e12 The Journal of Thoracic and Cardiovascular Slimits from 42 days in the United States and 35 days in
the United Kingdom is a solution to this issue.207 Modifica-
tion of RBC storage techniques is another.208 Prospective
trials need to be done, however, to show the improvements
achieved by shorter storage limits or modified storage tech-
niques, because adoption of either of the suggested strate-
gies would have significant economic implications.
There is also evidence to suggest that patient-related
factors such as age and comorbidity are importantsfusion on postoperative infection (sepsis, bacteremia, or any infection).
urgery c August 2011
FIGURE 3. Forest plot of studies evaluating the effect of red blood cell transfusion on postoperative acute renal failure or renal replacement therapy and on
acute kidney injury. IV, Inclusive value; CI, confidence interval.
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issue is central to clinical transfusion practice. From obser-
vational studies, it is apparent that older patients and those
with comorbidity are transfused more frequently than are
younger, fitter patients.1,2,21,23,26,65,184-193,196-199 Whether
older and sicker patients are more likely to have complica-
tions associated with anemia, as opposed to transfusion, is
unknown. In the TRICC study, for example, a subgroup
analysis demonstrated a significantly higher mortality in
the liberal threshold group among younger and less ill pa-
tients.200 A subgroup analysis of retrospective data inFIGURE 4. Forest plot of studies evaluating the effect of RBC transfusion on
output). IV, Inclusive value; CI, confidence interval.
The Journal of Thoracic and Cardiocardiac surgery did not support this; the association
between transfusion and adverse outcome did not differ
between patients of different ages, or in those with greater
comorbidity.26
Significant gaps in our understanding of the relationship
between transfusion and outcome remain. Changing clini-
cal practice or justifying the economic costs of changes in
blood processing or storage is unlikely to occur without
robust evidence from high-quality RCTs.
Areas of uncertainty and topics for further study. Areas
for further study include an assessment of the adversepostoperative cardiac morbidity (major cardiac complication, low cardiac
vascular Surgery c Volume 142, Number 2 249.e13
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ing of the mechanism by which this occurs might lead to
a better definition of indications in which RBC transfusion
may be appropriate.
Laboratory and Point-of-Care Tests
Hemorrhagic diathesis resulting fromCPB is awell-known
but only partially understood phenomenon. The hemostatic
defects that occur are an additive composite of exposure of
the blood to an extracorporeal circuit, anticoagulation of the
blood with heparin, heparin reversal with protamine, and
the dilution and consumption of existing coagulation factors
and platelets. To optimize these factors to preserve the hemo-
static system, it has been recommended that heparin adminis-
tration and blood transfusion be guided by rapid-turnaround
point-of-care testing. There is no universal heparin dosing
scheme or any definitive ACT that confers safety in CPB.
Furthermore, although the literature supports point-of-care
testing of platelet function to support transfusion algorithms,
it is unclear whether the instrument, the behavior, or both,
contribute to the reduction in transfusions seen when algo-
rithms are used.
Heparin. The point-of-care methods available for moni-
toring heparin anticoagulation during CPB include ACT,
heparin concentration, heparin management test, and other
coagulation tests, such as prothrombinase clotting time
and high-dose thrombin time.209 When cardiac surgery pro-
tocols were first developed, empirical heparin dosing proto-
cols were used, but these soon lost favor to heparin
protocols that were based on monitoring the ACT. Heparin
activity is determined by the activity of its cofactor anti-
thrombin and other physiologic and environmental vari-
ables. Variability of the patient response to heparin and
the absence of prospective literature confirming a safe range
for ACT values during CPB are the major impediments to
establishing firm guidelines for heparin dosing. Retrospec-
tive studies and case reports confirm that there is no magic
number for the therapeutic ACT value and that CPB can
probably be conducted safely with ACT values in the range
of 300 seconds and with reduced heparin doses.160 If a low
ACT strategy is accepted for CPB, however, coated tubing
should probably be used.210
Conversely, another concept that has received some sup-
port in the literature is that the microvascular coagulation
that occurs during CPB is best attenuated by the use of
higher doses of heparin.211,212 It is possible that the mini-
mum amount of heparin that can be safely used should
not be the goal. This idea originated from evidence that
ACT values increase on CPB while heparin concentration
decreases. The maintenance of a stable heparin concentra-
tion during CPB would thus result in the administration of
additional doses of heparin, despite a therapeutic ACT.
Maintenance of heparin concentration results in higher hep-
arin doses and potentially less activation of the coagulation249.e14 The Journal of Thoracic and Cardiovascular Sand fibrinolytic system. The hypothesis that this will result
in less bleeding and lower transfusion requirements has
been supported in some studies126,213 but has been refuted
in others.160,214 Even in the studies that support heparin
concentration-based monitoring and the resultant higher
heparin doses that are administered,213 however, the reduc-
tion in hemostatic activation is not always accompanied by
less clinical bleeding.
The ideal technique and therapeutic threshold for ACT
monitoring of heparin during CPB has yet to be established.
The initial dose of heparin that is required for an individual
patient to achieve a therapeutic ACT for initiation of CPB
can be individually tailored and calculated according to
an in vitro heparin dose–response curve. These curves can
be generated at the point of care and can be used to predict
accurately a patient’s need for heparin on the basis of
sensitivity. Individually tailored heparin and protamine
dosing215 determined by residual circulating heparin con-
centration has been successfully studied in cardiac surgery,
but evidence is not strong, and such practices have therefore
not been universally adopted.
Perioperative bleeding. Attenuation of the inflammatory,
coagulation, and fibrinolytic responses to CPB helps to min-
imize perioperative microvascular bleeding and the need for
transfusion of all allogeneic blood products.216 It is well
documented that these cascades are activated and play
a role in end-organ dysfunction associated with CPB. Extra-
corporeal circulation itself causes consumption of platelets
and coagulation factors. Activation of coagulation and fibri-
nolysis result in platelet count reduction and platelet de-
granulation during CPB. Fibrinolysis results in the
consumption of both coagulation factors and platelets, and
inflammation mediates lung injury and other end-organ dys-
function. Interventions aimed at preventing the activation of
these cascades are the first-line defense for reducing the
bleeding that results from CPB. It has been demonstrated
in the literature that tests of platelet function, measured in-
traoperatively and postoperatively (not preoperatively), cor-
relate best with the occurrence and time course of post-CPB
bleeding. Platelet number113,217 and bleeding time do not
have a strong relationship with perioperative bleed-
ing.218,219 Even point-of-care measures of fibrinolysis do
not strongly predict postoperative bleeding.220-223 The mea-
sure of platelet function during the intraoperative or postop-
erative period is thus critical to devising accurate and
appropriate transfusion strategies so that bleeding patients
can be treated with only those allogeneic blood products
that they actually need. This approach has been confirmed
by a small prospective study of thrombelastometry.223
Transfusion algorithms that incorporate a test of platelet
function have been the most successful in reducing transfu-
sions after cardiac surgery. Open questions include which
platelet function tests to use and which other measures
should be included in a transfusion algorithm.urgery c August 2011
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to measure platelet function have proved helpful in
reducing transfusion requirements in cardiac surgical pa-
tients, as reported in small, prospective studies.78,224-228
These algorithms can be further specified to qualify a coag-
ulation defect so that the amount of transfused blood prod-
uct needed can be predicted by the algorithm. Other
viscoelastic tests,229 platelet function tests,229-231 imped-
ance aggregometry,88 and hemostatometry232 have been
less well studied but have shown benefit for identifying
bleeding patients and for directing appropriate treatment.
Some of the studies that show a reduction in transfusions
demonstrate no significant effect on blood loss. It is there-
fore unclear whether the transfusion algorithm itself is re-
sponsible for the lower transfusion requirements or
whether instead the change in behavior represents a bias,
causing these studies to show benefit. Depending on the
conduct of CPB and the particular hemostatic abnormalities
that are expected, some investigations have shown that
point-of-care coagulation tests have the strongest correla-
tion with bleeding and should be included early in a transfu-
sion algorithm.233,234
The implementation of point-of-care testing requires an
investment by any institution that embraces it, but the cost
is far outweighed by the benefit if perioperative transfusions
are reduced. If patients at highest risk for transfusion could
be identified early in the perioperative course, these patients
would be the ones who could receive early initiation of
point-of-care testing and therefore derive the most benefit.
Accurate point-of-care tests to monitor platelet function
and other measures of coagulation function are in develop-
ment. In addition, novel anticoagulation strategies are being
investigated that may make the use of heparin during car-
diac surgery obsolete. Whether these developments will im-
prove outcomes after cardiac surgery also remains to be
determined.
Areas of uncertainty and topics for further study. The
current uncertainties that exist in point-of-care monitoring
for patients supported on CPB surround heparin monitoring
bleeding diagnostics. The optimal dose of heparin to
achieve the acceptable ACT for CPB is not yet known. In
evaluating bleeding after CPB, dynamic tests of platelet
function have helped to rationalize blood transfusion ther-
apy and minimize transfusions in the patient supported on
CPB; however, the most accurate hemostasis monitors
and tests of platelet function for incorporation into bleeding
algorithms have not yet been defined.
Pharmacologic Strategies to Reduce Bleeding
Apart from the trauma of surgery, bleeding in patients
who undergo cardiac surgery may result from impairment
of the hemostatic system. The most important mechanisms
that contribute to a hemostatic defect include the following:
(1) the loss of platelets and impairment of platelet functionThe Journal of Thoracic and Cardioas a result of CPB, (2) hemodilution with associated
decreased plasma concentrations of coagulation factors,
(3) incomplete neutralization of heparin given during
CPB, (4) an overdose of protamine sulfate (which may itself
inhibit coagulation), (5) preoperative use of anticoagulant
or antiplatelet drugs, (6) enhanced activity of the fibrino-
lytic system, in part as a result of circulating plasminogen
activators, and (7) low levels of physiologic anticoagulant
factors, resulting in ongoing consumption of coagulation
factors.
Pharmacologic agents that are capable of promoting he-
mostasis or fibrin formation or that can block fibrinolytic
activity may interfere with the balance between coagulation
activation and physiologic anticoagulation.235 Although
specific correction of these coagulation defects is highly ef-
fective and desirable, it is often difficult to achieve because
the underlying defect is not always immediately apparent,
and many mechanisms may be present simultaneously. For-
tunately, there is seldom a strong need to specifically target
a factor or pathway in the coagulation or fibrinolytic system
that is causally related to the hemostatic defect, because in-
terference in one part of the system may be able to compen-
sate for a defect in another part. Indeed, many clinical
studies support the efficacy of prohemostatic interventions
in patients undergoing cardiac surgery in terms of reduction
in perioperative blood loss and transfusion requirements.
The safety of prohemostatic therapy, however, also deserves
some consideration. Prohemostatic agents may, at least the-
oretically, predispose a patient toward thrombotic compli-
cations. Here we will briefly review the available clinical
evidence on efficacy and safety in cardiac surgery of the 3
types of prohemostatic strategies that have been most in-
tensely investigated: desmopressin, antifibrinolytic agents,
and recombinant activated factor VII (rFVIIa). For other
prohemostatic interventions, such as prothrombin complex
concentrate, fibrinogen concentrate, and factor XIII concen-
trate, there is no published systematic clinical evidence
available for patients undergoing cardiac surgery. These
therapies are therefore not discussed here; however, the
use of these compounds to reduce bleeding after cardiac
surgery is being investigated.
Desmopressin. Desmopressin (1-deamino-8-D-arginine) is
a vasopressin analog that, despite minor molecular differ-
ences, has retained its antidiuretic properties but has fewer
vasoactive effects.236 Desmopressin induces release of the
contents of the endothelial cell–associated Weibel-Palade
bodies, including large multimers of von Willebrand factor,
that are relatively active in promoting platelet adhesion to
the vessel wall. Indeed, the administration of desmopressin
results in a remarkable augmentation of primary hemosta-
sis. In 1986, Salzman and associates237 showed that desmo-
pressin (0.4 mg/kg) reduced blood loss and transfusion
requirements during complex cardiac surgery by approxi-
mately 30%. Subsequent attempts to reproduce thesevascular Surgery c Volume 142, Number 2 249.e15
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marked benefit originally described.238,239 A few meta-
analyses have indicated that although desmopressin
helps to reduce perioperative blood loss, the effect is too
small to influence other, more clinically relevant outcomes,
such as the need for transfusion and reoperation.240-242
Studies on desmopressin in cardiac surgery are outdated
and were performed in an era when aggressive antiplatelet
therapies (thienopyridines) were less common. The role of
desmopressin in patients aggressively treated with new-
generation thienopyridines remains to be established.
Antifibrinolytic treatment. Agents that exert antifibrino-
lytic activity comprise aprotinin and the group of lysine ana-
logs.235,243 Aprotinin is a 58–amino acid polypeptide, mainly
derived from bovine lung, parotid gland, or pancreas, that di-
rectly inhibits the activity of various serine proteases, includ-
ing plasmin, coagulation factors or inhibitors, and
constituents of the kallikrein–kinin and angiotensin system.
Lysine analogs such as 3-aminocaproic acid and tranexamic
acid are inhibitors of fibrinolysis.243 The antifibrinolytic ac-
tion of lysine analogs is based on the competitive binding of
these agents to the lysine-binding sites of a fibrin clot, thereby
competing with the binding of plasminogen. Impaired plas-
minogen binding to fibrin delays the conversion of plasmino-
gen toplasmin and subsequent plasmin-mediatedfibrinolysis,
which then proceeds at an inefficient and slow rate. Subtle
molecular variations among the different lysine analogs
may have important consequences for their fibrinolysis-
inhibiting capacity. Indeed, tranexamic acid is at least 10
times more potent than 3-aminocaproic acid.
The efficacy of antifibrinolytic agents in cardiac surgery
has been evaluated in several systematic reviews.241,244-247
The Cochrane group247 analyzed 211 RCTs with 20,781
participants that were published before July 2006. The
vast majority of trials (147 of 211) enrolled patients under-
going cardiac surgery. Ninety-eight studies evaluated apro-
tinin in 5750 patients randomly allocated to aprotinin and
4394 control patients. RCTs of tranexamic acid and 3-ami-
nocaproic acid were much less numerous: 53 RCTs (3836
patients) investigated tranexamic acid, and only 14 RCTs
(801 patients) studied 3-aminocaproic acid. Both aprotinin
and tranexamic acid reduced transfusion of allogeneic
blood by approximately 30% and helped to save approxi-
mately 1 unit of blood per operation, with a nonstatistically
significant trend toward a similar reduction with 3-amino-
caproic acid. These figures should be interpreted with cau-
tion, however, because of the substantial intercenter
variation in blood-saving techniques and transfusion prac-
tices, for example because of different transfusion triggers.
Importantly, the meta-analyses show that the use of antifi-
brinolytic agents may result in a 2- to 3-fold reduction in
the need for surgical reexploration as a result of bleeding.
The safety of aprotinin was questioned by a study in 4374
patientswhounderwent electiveCABG.248The studywas ob-249.e16 The Journal of Thoracic and Cardiovascular Sservational and nonrandomized, but it did use a propensity
score method to balance the covariates. Compared with un-
treated control patients, aprotinin (but neither 3-aminocaproic
acid nor tranexamic acid) doubled the occurrenceof severe re-
nal failure, increased the incidence of myocardial infarction
or heart failure by 55%, and was associated with a nearly
2-fold increase in stroke or other cerebrovascular events. Sub-
sequently, similar results were found in 2 other studies249,250
and in anobservational survey conductedby themanufacturer
in 67,000 patients undergoing cardiac surgery.251 A prospec-
tive, randomized trial comparing aprotinin and lysine analogs
in 2331 high-risk cardiac surgical patients confirmed a higher
30-day mortality in the aprotinin group (6.0%), versus 3.9%
in the tranexamic acid group and 4.0% in the 3-aminocaproic
acid group.252 On the basis of all these findings, the US Food
and Drug Administration suspended the license of aprotinin
in the United States, and the manufacturer halted the global
distribution of the agent. All in all, tranexamic acid (most fre-
quently used total dose3–10g, usually distributedas a loading
dose of 2–7 g and a maintenance dose of 20–250 mg/h) is the
most appropriate antifibrinolytic agent for use in high risk car-
diac surgery. It is not clear from the literature, however, which
patientswill benefitmost from this treatment,what is themost
effective dose with the least side effects,253 and how to select
patients perioperatively who should receive tranexamic acid.
Recombinant activated coagulation factor VII. On the
basis of the current insight that activation of coagulation
in vivo predominantly proceeds by the tissue factor and fac-
tor VII pathway, rFVIIa has been developed as a prohemo-
static agent and is now available for clinical use254 and has
been licensed for the prevention and treatment of bleeding
in patients with antibodies to coagulation factors VIII or
IX, so-called inhibitors. In addition, abundant case reports
and case series on the hemostatic efficacy of rFVIIa in pa-
tients undergoing surgery have been published.255 Virtually
none of these reports have included adequate controls, how-
ever, which makes it very difficult to draw any clinical con-
clusion. Nevertheless, there is widespread off-label use of
rFVIIa for patients with excessive blood loss who have
failed conventional treatment. There is limited experience,
mostly published as case series or retrospective cohort
studies, with rFVIIa in patients undergoing cardiac sur-
gery.256,257 A small RCT in 20 adult patients undergoing
complex noncoronary cardiac surgery requiring CPB evalu-
ated rFVIIa.258 Administration of this agent (90 mg/kg) after
discontinuation of bypass and reversal of heparin signifi-
cantly reduced the need for blood transfusion (relative risk
of any transfusion, 0.26; 95% confidence interval, 0.07–
0.90). A recent phase II dose-escalation, placebo-controlled
study in 172 patients with major blood loss after cardiac sur-
gery showed that the administration of rFVIIa resulted in less
blood loss, a significant reduction in the need for reoperation
(25% in the placebo group, 14% in the group receiving
rFVIIa at 40 mg/kg, and 12% in the group receiving rFVIIaurgery c August 2011
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not needing any transfusion (10% in the placebo group, 28%
in the group receiving rFVIIa at 40 mg/kg, and 32% in the
group receiving rFVIIa at 80mg/kg).259More serious adverse
events were reported in patients treated with rFVIIa (13% vs
7% in the placebo group, difference not significant). Indeed,
in view of its prohemostatic activity and potential for throm-
botic adverse events, the safety of rFVIIa has been the subject
of much attention and surveillance. In clinical RCTs, admin-
istration of this agent resulted in a relatively low incidence of
thrombotic complications, comparable to that seen among
placebo-treated patients254; however, most of these studies
were performed in patients with impaired coagulation or at
low risk for thrombosis. In the trial carried out in patients
with a much higher risk, such as those with intracerebral
hemorrhage, serious thromboembolic events, mainly myo-
cardial or cerebral infarction, occurred in 7% of patients
treated with rFVIIa compared with 2% of placebo-treated
patients. There is thus some indication that rFVIIa may in-
crease the risk of thrombotic complications, and this needs
to be balanced with its potential benefit in patients with se-
vere blood loss. More RCTs are needed to establish efficacy
and safety in patients undergoing cardiac surgery.260
Areas of uncertainty and topics for further study. Be-
cause the window between benefit and risk of various pro-
hemostatic options is relatively small, it is important,
aside from the specific properties of the various interven-
tions, to look critically to patient selection for this type of
treatment. Prohemostatic agents may provide a relatively
large benefit for patients undergoing surgery that carries
a high risk of bleeding (reoperative surgery, combined
procedures, and so on). In less complex cases, the prohemo-
static benefit may be annihilated by the side effects of the
intervention. Apart from retrospective subgroup analyses,
however, there has been surprisingly little study on which
procedures may be best suited for the concomitant use of
prohemostatic strategies. Apart from the surgical interven-
tion, patient factors may also affect the expected benefit–
harm balance for prohemostatic interventions, and here
even less is known. Future prospective studies could focus
on identifying patient criteria and situations that warrant
the use of prohemostatic interventions.
A further issue is the lack of properly validated monitor-
ing tools to guide prohemostatic interventions in patients
undergoing cardiac surgery. Dosing of prohemostatic drugs
may therefore be problematic, and it is likely that the ‘‘one
size fits all’’ strategy that is now generally adopted results in
marked underdosing or overdosing of individual patients.
Future studies should aim to develop and validate properly
monitoring systems to properly dose individual patients
during and after cardiac surgery.
Another area for further research is the efficacy and safety
of alternative prohemostatic interventions. Coagulation fac-
tor concentrates, including fibrinogen concentrate, FXIII,The Journal of Thoracic and Cardioand rFVIIa, have a marked effect on laboratory parameters
of coagulation, but it is not clear how this translates into
a beneficial effect on clinically relevant outcomes. In addi-
tion, the safety of these interventions has been studied only
marginally in patients undergoing cardiac surgery.261,262
Patient Blood Management Policy
The current magnitude of transfusion costs. According
to the US blood collection and utilization survey for 2006,
the product cost for RBCs was $3.2 billion.6 This, however,
represents only a part of the overall financial burden of
transfusion. In addition to product cost, there are many
other cost elements involved, and attempts have been
made to determine those by means of process flow
analyses.263,264 The panelists of the first multidisciplinary
Cost of Blood Consensus Conference recognized the limita-
tions of this methodology and proposed that the next itera-
tion to determine the totality of transfusion-related costs
would be process cost analysis, also known as activity-
based costing.265 Subsequently, this methodology was ap-
plied in the surgical setting at 4 centers. In the 2UShospitals,
the total costs per unit transfused were $726 and $1183,
representing 3.2 to 4.8 times the acquisition cost for
RBCs.266 As determined from the $3.2 billion cost volume
forRBCs and the lower bound ratio of 1:3.2, the extrapolated
RBC transfusion-related direct cost for US health care pro-
viders could be $10.2 billion, with an upper bound of $15.4
billion. This figure, however, does not include elements that
contribute to the total societal cost of blood, including donor
costs, hemovigilance, lost productivity, and midterm to
long-term adverse transfusion outcomes.267 Even without
considering these additional factors, the cost of RBC trans-
fusions represents a major economic dimension. Activity-
based cost studies for plasma and platelet transfusions are
still needed for a more complete picture.
The futuremagnitude of transfusion costs. Thewidening
gap between supply and demand for allogeneic blood com-
ponents is expected to escalate the cost of transfusion. The
supply side is increasingly under pressure in response
a changing ratio between the donating and the nondonating
population. To measure the effect of this shift, a socioeco-
nomic metric called old age dependency ratio can be applied
in a slightly altered form. It divides the nonworking popula-
tion aged 65 years by the working population aged 15 to 64
years, multiplied by 100. The 2005 old age dependency ratio
for 25 European Union countries was 24.8, meaning that
a mean of 24.8 elderly persons depended on 100 working in-
dividuals. In the past 20 years, the ratio in the EU has risen
from approximately 20 to 25. According to migration trends
and birth and death rates in high human development index
countries, it will climb to almost 40 during the next 20
years.268 With slight changes, this metric has been intro-
duced as a total transfusion dependency ratio (Equation 1),
relating the non–blood-donating population of individualsvascular Surgery c Volume 142, Number 2 249.e17
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population of individuals aged 18 to 64 years268:
TTDR ¼ PND
PD
3 100 [1]
where PND is the non–blood-donating (dependent) popula-
tion, aged 0 to 17 years plus 65 years and older, and PD is
the blood-donating population, aged 18 to 64 years.
If current donation patterns continue, TTDR in developed
countries will more or less double during the next 20 years.
Moreover, a recent Canadian study showed that the most
generous segment of blood donors (15–24 years of age) is
shrinking in both absolute and relative terms.269
The problem on the demand side is even more challeng-
ing. Wells and colleagues270 showed that most blood is used
in treatment of the older age segments of the population.
Because older patients are by far the fastest growing group,
this demographic trend has a leveraging effect on blood use.
An analysis in Western Australia showed that patients 70
years old and older received 179.6 RBC units per 1000 pop-
ulation, compared with 33.5 in the 40- to 69-year age seg-
ment and only 10.7 in the 0- to 39-year age segment. The
use of RBC units in the segment of patients at least 70 years
old accounted for more than 45% of all RBCs transfused.271
If current donation and transfusion behavior prevails, blood
shortage will therefore become chronic, and, following the
law of supply and demand, component cost will rise sharply.
Model calculations have yet to be performed.
Problems with health economic analyses comparing
transfusion with patient blood management modalities.
The burden of current and future transfusion cost necessi-
tates comparative evaluations of other hemotherapeutic op-
tions: patient blood management modalities such as ANH,
intraoperative cell salvage, anemia management with
erythropoietin-stimulating agents or iron, bleeding man-
agement with various hemostatic agents, point-of-care di-
agnostics, and others. The appropriate health policy
decision-making tool would be the incremental cost-
effectiveness ratio (ICER; Equation 2), defined as the
change in costs (C) of a therapeutic intervention (relative
to the best available alternative treatment or to doing noth-
ing) relative to the change in effects (E). The effect is ex-
pressed in outcome measures such as life years gained,
quality-adjusted life years gained, the number of deaths
prevented, the number of infections prevented, the number
of symptom-free days, or other parameters. For the compar-
ison of standard transfusion with patient blood manage-
ment, the equation to calculate the ICER is as follows:
ICER ¼ CPBMXCTxn
EPBMXETxn [2]
where CTxn is the average total cost in the transfusion co-
hort, CPBMX is the average total cost in a cohort treated249.e18 The Journal of Thoracic and Cardiovascular Swith patient blood management modality X, ETxn is the total
effectiveness in the transfusion cohort, and EPBMX is the to-
tal effectiveness in the cohort treated with patient blood
management modality X.
Unlike in other fields of pharmacoeconomics, the litera-
ture shows a paucity of evidence to determine both the
costs and the effects of most, if not all, patient blood man-
agement modalities. Some studies have investigated the
cost-effectiveness of ANH versus allogeneic RBC transfu-
sions, but none have been based on process cost analyses.
Others have compared autologous with allogeneic RBC
transfusions or leukodepleted with nonleukodepleted
RBC transfusions but have not compared patient blood
management modalities. Most importantly, there is little
evidence for a positive effect of RBC transfusion with
the exception of extreme or acute bleeding settings.29 On
the contrary, a large number of observational studies
have shown transfusion to be independently associated in
a dose-dependent manner with increased mortality and
morbidity, including nosocomial infection, sepsis, pneu-
monia, ischemic events, acute respiratory distress syn-
drome, acute lung injury, and multiorgan failure, along
with increased ICU admission and lengthened ICU and
hospital stays.10,25,26,272-278 Only high-powered RCTs or
the systematic application of the Bradford-Hill criteria
for assessing evidence of causation279 will yield sufficient
evidence to determine whether transfusion is a cause of
these adverse outcomes. If the relation is causal, the over-
all costs of transfusion will significantly exceed current
calculations.
Results of patient blood management programs. Al-
though evidence is still lacking to determine the cost-
effectiveness of specific patient bloodmanagement modalities,
clinicians and hospital administrators should not ignore the
fact that patient blood management programs have re-
sulted in savings in terms of avoided allogeneic RBC
transfusions and in general have been cost-effective.280,281
Blood conservation programs in the 1990s showed signif-
icant reductions in blood use with improved outcomes.280
Englewood Hospital and Medical Center in New Jersey re-
ported a 42% reduction in blood use during the first 4
years of their program. Since its inception, the cardiac
surgery program at this center has used a broad-based blood
conservation programfor all patientswhoare admitted for car-
diac surgery.281 In this single-center study, an overall transfu-
sion rate of 13% among patients undergoing CABG, valve
operations, and CABG with valve operations was reported.
Furthermore, these achievements have been maintained
without any increase inmorbidity andmortalitywhen stratify-
ing patients undergoing isolated CABG surgery.271,281,282
Other centers have also reported findings of reductions in
transfusions for patients undergoing cardiac surgery, with
lower costs for blood product acquisition and substantial
savings related to shortened stay and lower incidences ofurgery c August 2011
TABLE 2. Factors discussed here for which further research may provide a higher level of evidence for clinical practice in cardiac surgery
Factor Limitations of current evidence Issues for future research
Acute normovolemic hemodilution Temporal effect of storage on oxygen-carrying
capacity of blood products unclear
Does short-term storage of blood products affect
effectiveness?
Data lacking on patient subpopulations What are the appropriate hemodilution targets in
different patient subpopulations?
Data lacking on patient subpopulations What are the benefits of acute normovolemic
hemodilution in different patient subpopulations?
Acute platelet pheresis Methodology not standardized Does higher platelet yield correlate with
effectiveness?
Lack of evidence in patient subpopulations Do antiplatelet agents affect the quality of the
product?
Adverse outcomes All available clinical evidence is associative not
causal
Does transfusion cause adverse outcomes?
Anticoagulation Limited data on the effectiveness of alternative
anticoagulants
Are alternative anticoagulation agents safer andmore
effective than heparin?
Anticoagulation measurement Optimal measure and threshold unclear Which is the optimal method with which to monitor
anticoagulation?
What are the minimum acceptable target threshold
levels?
Anticoagulation measurement Lack of data on the significance of antithrombotic
activity in anticoagulation
Should antithrombotic activity be measured
preoperatively?
Does antithrombotic activity correlatewith outcome?
Lack of data on the significance of endogenous
endothelium-derived factor activity in
anticoagulation
Should the activity of other endogenous
endothelium-derived factors be measured?
Unclear whether inadequate ACT response to
heparin reflects inadequate anticoagulation
Should low ACT activity be supplemented in
heparin-exposed patients?
Biocompatible CPB circuits Data lacking on newer (nonheparin or
multimolecular) coatings
Do coatings other than heparin offer any additional
benefit?
Closed vs open circuits No evidence that closed circuits alone reduce
transfusion rate
Does separation of cardiotomy shed blood decrease
blood activation, bleeding, and transfusion rate?
Extreme-risk patients Population poorly defined Is patient blood management strategy different in
extreme-risk patients?
Hemoglobin Poor evidence for relationship among transfusion,
hemoglobin, and tissue oxygenation
Which other markers for transfusion might
supplement hemoglobin?
Unknown differences in quality of endogenous vs
exogenous hemoglobin
Does transfusion improve tissue oxygenation?
What is the oxygen-carrying capacity of hemoglobin
ex vivo?
Temporal variability of hemoglobin is not well
characterized
What is the clinical impact of temporal changes in
hemoglobin?
High-risk groups All available clinical evidence is associative, not
causal
Does the relationship between transfusion and
adverse outcomes vary in different patient
subpopulations?
Indicators and discriminators
of effectiveness
Insufficient evidence Are there easily-measurable objective indicators or
discriminators of patient subpopulations that may
benefit from transfusion?
Mini-CPB Too few patients and single components compared in
existing randomized, controlled trials
Does the use of a comprehensive strategy result in
fewer transfusions?
Platelet function testing No randomized data available Can randomized clinical trials provide higher-level
data?
Optimal device unclear Can technologic improvements be validated?
Appropriate acceptable values to determine optimal
pre-surgical platelet inhibition level not well-
defined
Which range of platelet inhibition minimizes
thromboembolic/hemorrhagic risk?
(Continued)
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TABLE 2. Continued
Factor Limitations of current evidence Issues for future research
Appropriate point-of-care methodology to determine
the degree of platelet inhibition unclear
Which platelet function test is most useful to
determine platelet inhibition?
Point-of-care testing Appropriate point-of-care methodology for testing to
guide treatment of the bleeding patient unclear
Which tests of heparin neutralization and hemostasis
are optimal for use in an algorithm for the bleeding
patient?
Preoperative donation Lack of sufficient data to change clinical practice;
benefit vs allogeneic blood products unclear
What are the benefits of autologous donation?
Is autologous donation cost-effective?
Presurgical management Timing of surgery in patients receiving dual
antiplatelet therapy not well characterized
Does platelet function testing minimize transfusion
in patients treated with anti-platelet agents?
Is the transfusion rate dependent on the timing of
antiplatelet therapy withdrawal before surgery?
Reduced hemodilution during CPB Lack of data related to temporal exposure to low
hemoglobin
Is less perioperative variation in hemoglobin
associated with a lower transfusion rate?
Is the time of exposure to a low hemoglobin more
important than nadir hemoglobin?
Reduced systemic heparinization Heparin dose and target ACT not clearly defined;
lack of high-level evidence
Does reduction of systemic heparinization in the
setting of biocompatible circuits decrease bleeding
and transfusion rate?
rSO2 Qualitative marker of regional tissue oxygenation;
unclear correlation with global oxygenation;
normal values and methodology not well defined
Is rSO2 useful in the transfusion decision-making
process?
May be increased by blood transfusion Is rSO2 useful as (part of) a transfusion trigger?
ScvO2 SvO2 Clinical data limited; animal data may not be
transferable to human patients
Is ScvO2 or SvO2 superior to hemoglobin as a trigger
for transfusion?
Shed blood processing Unclear whether washing cardiotomy shed blood
results in loss of platelets and coagulation factors
What is the amount of blood that can be safely
processed?
Which shed blood processing method is most
effective?
Is shed blood processing cost-effective?
Storage duration All available clinical evidence is associative, not
causal
Is storage time a factor in the relationship between
transfusion and adverse outcomes?
Timing of surgery Only small, single-center trials have been reported Can prospective, randomized multicenter trials
provide higher-level data?
Transfusion trigger No validated physiologic transfusion triggers Could a physiologic transfusion trigger replace
a static (hemoglobin) trigger?
ACT, Activated clotting time; CPB, cardiopulmonary bypass; rSO2, regional cortical oxygen saturation; ScvO2, central venous oxygen saturation; SvO2, mixed venous oxygen
saturation.
Editorial Ranucci et al
E
D
IT
O
R
IA
Lcomplications.280,283-285 It is therefore essential to produce
sufficient evidence for cost-effectiveness analyses across all
major patient blood management modalities to identify those
with the most impact.
Areas of uncertainty and topics for further study. The
cost of RBC transfusion from a health care provider’s per-
spective is higher than previously assumed. The intended
effects of transfusion, apart from hemoglobin rise, in most
patient populations have not been satisfactorily demon-
strated. Conversely, a number of observational studies
show that many unintended or negative outcomes are asso-
ciated with transfusion. The cost-effectiveness of RBC
transfusion is therefore unclear. Patient blood management
programs have been demonstrated to be cost-effective over-
all, but it is unclear to what degree specific patient blood
management modalities have contributed to the effective-249.e20 The Journal of Thoracic and Cardiovascular Sness. More evidence is necessary for meaningful ICERs,
allowing optimal resource allocation.Concluding Remarks
The aim of this article has been to evaluate existing pub-
lished evidence related to patient blood management in car-
diac surgical patients to generate an inventory or ‘‘wish list’’
of areas that urgently require further research before truly
evidence-based recommendations to optimize patient care
can be made. The primary areas in which further research
is required and suggested issues to be addressed are summa-
rized in Table 2. The IIHMCS author group believes that the
following issues should be given the highest priority:
 Although hemoglobin levels are currently used as the stan-
dard measure of organ dysoxia, hemoglobin may be anurgery c August 2011
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Linadequate trigger for transfusion. In the very low range,
measured hemoglobin levels may be helpful in guiding pa-
tient management; in the range typically seen in cardiac
surgery clinical practice, however, we suggest that other
physiologicmarkersmayusefully supplement hemoglobin.
 It is currently unclear whether limiting excessive hemo-
dilution during CPB thereby limits transfusion needs,
and controlled studies in this area are warranted.
 The impact of patient comorbidity, the age of stored
RBCs, and the presence of a regional oxygen supply de-
pendency on patient outcomes as a result of transfusion is
unclear and requires further study.
 Elucidation of the role of closed versus open CPB circuits
and larger studies on mini-CPB are needed.
 The optimal dose and monitoring of heparinization and
heparin reversal remain to be established.
 Further research is needed into the use of both current
and new antifibrinolytics and anticoagulants.
 The appropriate application of fresh-frozen plasma and
platelet transfusions.
 In patients who receive preoperative antiplatelet agents,
specific point-of-care platelet function tests should be ex-
plored for their capacity to detect patients at high risk for
postoperative bleeding and transfusion.
 Prohemostatic agents may provide the most benefit in pa-
tients at highest risk of bleeding; however, little is known
about which procedures and patient subgroups might
benefit most from prohemostatic interventions. Properly
validated monitoring tools to guide prohemostatic inter-
ventions are also needed.
 Some patient subpopulations are at exceptional risk for
receiving blood products and experiencing poor out-
comes, and they require careful monitoring and manage-
ment; however, few data to date support management
decisions in these small patient groups.
 An assessment of the cost-effectiveness of ANH in differ-
ent patient populations is also needed.
 We suggest that a rigorous cost analysis be undertaken to
evaluate the optimal period between cessation of antico-
agulation therapy and surgery.
 The cost of RBC transfusion is high, and the cost-
effectiveness unclear. Some patient blood management
programs have demonstrated cost-effectiveness, but the
contributing modalities are unclear and require further
investigation.
 Physician education is needed to ensure adherence to
clinical practice guidelines.
The creation of the term patient blood management re-
flects a paradigm shift from blood transfusion to blood man-
agement policies that incorporate multimodal blood
conservation strategies. To optimize these strategies in car-
diac surgery, further data are required in many areas. Some
of these data will best be generated in the context of clinicalThe Journal of Thoracic and CardioRCTs. Other questions may best be answered by expanding
or modifying existing database fields to collect data on, for
example, specific patient subpopulations and long-term out-
comes. We therefore encourage researchers, professional
societies, funding agencies, and industrial partners to focus
their attention on the areas that we have highlighted here.
With the support of a more solid evidence base, we hope
that future management guidelines can not only be adapted
to reflect new insights into optimal patient management but
also universally adopted into clinical practice.References
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APPENDIX TABLE 1. Literature search strategies
Topic, subtopic, and MeSH terms Date* No. of hits
Cardiopulmonary bypass
 Pump type
 Circuit type (closed vs open)
 Minimal cardiopulmonary bypass technology
 Impact of different kinds of coating
 Heparin management—reduction of systemic heparinization
 Hemodilution—impact on transfusions
 Techniques to reduce hemodilution (retro-prime, etc)
 Shed blood management—cell saving
 Ultrafiltration
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Cardiopulmonary Bypass’’[MeSH] OR
‘‘Cardiopulmonary Bypass/methods’’[MeSH])
April 14 188
Preoperative and perioperative fluid and hemodilution management
 Preoperative fluid management
 Colloids vs crystalloids
 Postoperative fluid management
 Preoperative conditions—body surface area, body mass index, anemia, etc
 Strategies to increase the hemoglobin value
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Fluid Therapy’’[MeSH] OR ‘‘Blood
Volume’’[MeSH] OR ‘‘Solutions’’[MeSH] OR ‘‘Colloids’’[MeSH] OR ‘‘Hetastarch’’[MeSH] OR ‘‘crystalloid solutions’’
[Substance Name] OR ‘‘Hematocrit’’[MeSH] OR ‘‘Erythrocyte Indices’’[MeSH] OR ‘‘Anemia’’[MeSH] OR ‘‘Serum
Albumin’’[MeSH] OR ‘‘Body Mass Index’’[MeSH] OR ‘‘Cardiac Output, Low’’[MeSH] OR ‘‘Blood Pressure’’[MeSH])
April 9 96
Physiologic signs of organ dysoxia during and after operation
 Mixed venous oxygen saturation and central venous oxygen saturation—acceptable range
 Serum lactates
 Factors affecting the alveolar–arterial oxygen difference—ventilation, cardiac output
 Markers of organ dysoxia—cardiac (troponin), renal, visceral organs
 New anticoagulants and heparin
 Influence of hematocrit on perioperative myocardial infarction, mesenteric ischemia
 Association between hemoglobin content and organ dysfunction
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Extracorporeal Circulation’’[MeSH] OR
Extracorporeal Membrane Oxygenation[MeSH] OR ‘‘Respiration, Artificial’’[MeSH] OR ‘‘High-Frequency
Ventilation’’[MeSH] OR ‘‘Liquid Ventilation’’[MeSH] OR ‘‘Positive-Pressure Respiration’’[MeSH] OR ‘‘Ventilator
Weaning’’[MeSH])
April 29 214
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’
[Publication Type] OR ‘‘Randomized Controlled Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR
‘‘Guideline’’ [Publication Type] OR ‘‘Practice Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND
(‘‘Anoxia’’[MeSH] OR ‘‘Blood Gas Analysis’’[MeSH] OR ‘‘Oxygen Consumption’’[MeSH]) AND (‘‘Cardiac
Output’’[MeSH] OR ‘‘Stroke Volume’’[MeSH])
April 29 30
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’
[Publication Type] OR ‘‘Randomized Controlled Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR
‘‘Guideline’’ [Publication Type] OR ‘‘Practice Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND
(‘‘Acid-Base Equilibrium’’[MeSH] OR ‘‘Acid-Base Imbalance’’[MeSH] OR ‘‘Acidosis’’[MeSH])
April 29 15
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APPENDIX TABLE 1. Continued
Topic, subtopic, and MeSH terms Date* No. of hits
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Anoxia’’[MeSH] OR ‘‘Cell Hypoxia’’[MeSH]
OR ‘‘Hypoxia, Brain’’[MeSH])
April 29 5
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’
[Publication Type] OR ‘‘Randomized Controlled Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR
‘‘Guideline’’ [Publication Type] OR ‘‘Practice Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND
(‘‘Anoxia’’[MeSH]OR ‘‘BloodGas Analysis’’[MeSH]OR ‘‘OxygenConsumption’’[MeSH]) AND (‘‘Brain’’[MeSH]OR
‘‘Brain/blood supply’’[MeSH] OR ‘‘Brain/diagnosis’’[MeSH] OR ‘‘Kidney’’[MeSH] OR ‘‘Kidney/blood
supply’’[MeSH] OR ‘‘Kidney/diagnosis’’[MeSH] OR ‘‘Heart’’[MeSH] OR ‘‘Heart/diagnosis’’[MeSH] OR
‘‘Troponin’’[MeSH])
April 29 55
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’
[Publication Type] OR ‘‘Randomized Controlled Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR
‘‘Guideline’’ [Publication Type] OR ‘‘Practice Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND
(‘‘Anoxia’’[MeSH] OR ‘‘Cell Hypoxia’’[MeSH] OR ‘‘Hypoxia, Brain’’[MeSH])
July 2 33
Clinical assessment, decision, and judgment
 Impact of invasive procedures before the operation
 Strategies to optimize the coagulation profile before the operation
 Role of anti-platelet drugs—time for withdrawal
 Blood loss assessment (timing and amount)
 Reoperation (timing and impact on transfusion)
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Heart Catheterization’’[MeSH] OR
‘‘Angioplasty, Transluminal, Percutaneous Coronary’’[MeSH] OR ‘‘Catheter Ablation’’[MeSH] OR ‘‘Preoperative
Care’’[MeSH])
April 9 208
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Platelet Aggregation Inhibitors’’[MeSH] OR
‘‘Hemorrhage/chemically induced’’[MeSH]) AND ‘‘Time Factors’’[MeSH]
April 9 23
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND ‘‘Blood Loss, Surgical’’[MeSH] AND ‘‘Time
Factors’’[MeSH]
April 9 17
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND ‘‘Reoperation’’[MeSH] AND ‘‘Time
Factors’’[MeSH]
April 9 5
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Heart Catheterization’’[MeSH] OR
‘‘Angioplasty, Transluminal, Percutaneous Coronary’’[MeSH] OR ‘‘Catheter Ablation’’[MeSH] OR ‘‘Preoperative
Care’’[MeSH])
April 9 208
(Continued)
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APPENDIX TABLE 1. Continued
Topic, subtopic, and MeSH terms Date* No. of hits
Blood management policy
 Nonmedical strategies to reduce blood product use
 Health economic analyses that includes both cost of transfusion metrics and cost of nontransfusion
 Overtransfusion rather than nontransfusion
 All cost-effectiveness assessments on safety rather than intended effectiveness
‘‘Cardiac Surgical Procedures’’[MAJR] AND (‘‘Blood Loss, Surgical’’[MAJR] OR ‘‘Postoperative Hemorrhage’’[MAJR]
OR ‘‘Hemostasis’’[MAJR] OR ‘‘Hemostatic Techniques’’[MAJR] OR ‘‘Blood Component Transfusion’’[MAJR]) AND
(‘‘Health Policy’’[MeSH] OR ‘‘Health Care Quality, Access, and Evaluation’’[ MeSH] OR ‘‘Outcome Assessment
(Health Care)’’[ MeSH] OR ‘‘Delivery of Health Care’’[ MeSH] OR ‘‘Health Services Research’’[ MeSH] OR
‘‘Economics’’[ MeSH] OR ‘‘Costs and Cost Analysis’’[ MeSH] OR ‘‘Economic Competition’’[ MeSH] OR ‘‘Economics,
Hospital’’[ MeSH] OR ‘‘Economics, Medical’’[ MeSH] OR ‘‘Economics, Pharmaceutical’’[ MeSH])
April 29 546
Blood product administration
 Time relationship between blood product administration and adverse events
 Adverse events with respect to the amount of PRBCs received
 Adverse events with respect to the storage time of the PRBCs received
 Adverse events with respect to each allogeneic blood product (PRBCs, fresh-frozen plasma, platelets)
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’
[Publication Type] OR ‘‘Randomized Controlled Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR
‘‘Guideline’’ [Publication Type] OR ‘‘Practice Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND
((‘‘Blood Component Transfusion’’[MeSH] OR ‘‘Erythrocyte Transfusion’’[MeSH] OR ‘‘Platelet Transfusion’’[MeSH]
OR ‘‘Plasma’’[MeSH]) AND (‘‘Outcome Assessment (Health Care)’’[MeSH] OR ‘‘Time Factors‘‘[MeSH]) OR
(‘‘Leukocyte Reduction Procedures’’[MeSH] OR ‘‘Blood Donors’’[MeSH]))
April 29 58
‘‘Cardiac Surgical Procedures’’[MeSH] AND ((‘‘Blood Component Transfusion’’[MeSH] OR ‘‘Erythrocyte
Transfusion’’[MeSH] OR ‘‘Platelet Transfusion’’[MeSH] OR ‘‘Plasma’’[MeSH]) AND (‘‘Outcome Assessment (Health
Care)’’[MeSH]OR ‘‘TimeFactors‘‘[MeSH])OR (‘‘LeukocyteReductionProcedures’’[MeSH]OR ‘‘BloodDonors’’[MeSH]))
April 29 126
Adverse outcomes
 Definition of the major complications (myocardial infarction, atrial fibrillation, stroke, acute renal failure, infections)
 Relationship between transfusions and adverse outcomes
‘‘Cardiac Surgical Procedures’’[MeSH] AND ‘‘Erythrocyte Transfusion’’[MeSH] April 28 135
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’
[Publication Type] OR ‘‘Randomized Controlled Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR
‘‘Guideline’’ [Publication Type] OR ‘‘Practice Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND
‘‘Erythrocyte Transfusion’’[MeSH]
April 28 55
Pharmacologic strategies to reduce bleeding
 Type and dose of drugs used before and during the operation
 Type and dose of drugs used after the operation
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Hematologic Agents’’[MeSH] OR
‘‘Coagulants’’[MeSH] OR ‘‘Hemostatics’’[MeSH] OR ‘‘Antifibrinolytic Agents‘‘[MeSH] OR ‘‘Heparin
Antagonists’’[MeSH] OR ‘‘Blood Coagulation Factors’’[MeSH] OR ‘‘Fibrin’’[MeSH] OR ‘‘Factor VII’’[MeSH] OR
‘‘Factor XIII’’[MeSH] OR ‘‘Thrombin’’[MeSH] OR ‘‘Fibrin Foam’’[MeSH] OR ‘‘Fibrin Tissue Adhesive’’[MeSH] OR
‘‘Deamino Arginine Vasopressin’’[MeSH])
April 14 392
Laboratory and point-of-care tests
 Routine laboratory (international normalized ratio, activated partial thromboplastin time) assays during and after operation
 Role of thromboelastography, platelet function tests in guiding the transfusion policy
 Advantages of heparin and protamine monitoring system
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Point-of-Care Systems’’[MeSH] OR
‘‘Hematologic Tests’’[MeSH] OR ‘‘Laboratory Techniques and Procedures’’[MeSH] OR ‘‘Platelet Count’’[MeSH])
April 28 261
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Topic, subtopic, and MeSH terms Date* No. of hits
High-risk subpopulations
 Mechanical assistance
 Explants
 Emergencies (acute aortic dissection, heart rupture, etc)
 Hypothermic cardiac arrest
 Adult congenital heart disease patients—cyanotic patients
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Artificial Organs’’[MeSH] OR ‘‘Heart,
Artificial’’[MeSH] OR ‘‘Heart-Assist Devices’’[MeSH] OR ‘‘Heart-Lung Machine’’[MeSH] OR ‘‘Pacemaker,
Artificial’’[MeSH])
April 29 14
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Emergencies’’[MeSH] OR ‘‘Heart
Rupture’’[MeSH] OR ‘‘Aortic Rupture’’[MeSH])
April 29 5
‘‘Cardiac Surgical Procedures’’[MeSH] AND (‘‘Blood Loss, Surgical’’[MeSH] OR ‘‘Postoperative Hemorrhage’’[MeSH]
OR ‘‘Hemostasis’’[MeSH] OR ‘‘Hemostatic Techniques’’[MeSH] OR ‘‘Blood Component Transfusion’’[MeSH]) AND
(‘‘Clinical Trial’’ [Publication Type] OR ‘‘Controlled Clinical Trial’’ [Publication Type] OR ‘‘Randomized Controlled
Trial’’ [Publication Type] OR ‘‘Meta-Analysis’’ [Publication Type] OR ‘‘Guideline’’ [Publication Type] OR ‘‘Practice
Guideline’’ [Publication Type] OR ‘‘Review’’ [Publication Type]) AND (‘‘Heart Defects, Congenital’’[MeSH] OR
‘‘Cardiac Output, Low’’[MeSH])
April 29 15
General limits included were English language, humans, all adults 19þ years, January 1994–April 2009. MeSH, Medical Subject Heading; PRBCs, packed red blood cells.
*All searches were conducted during 2009.
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